1
|
He W, Shen Y, Wohlfeld K, Sears J, Li J, Pelliciari J, Walicki M, Johnston S, Baldini E, Bisogni V, Mitrano M, Dean MPM. Magnetically propagating Hund's exciton in van der Waals antiferromagnet NiPS 3. Nat Commun 2024; 15:3496. [PMID: 38664432 PMCID: PMC11045826 DOI: 10.1038/s41467-024-47852-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2023] [Accepted: 04/11/2024] [Indexed: 04/28/2024] Open
Abstract
Magnetic van der Waals (vdW) materials have opened new frontiers for realizing novel many-body phenomena. Recently NiPS3 has received intense interest since it hosts an excitonic quasiparticle whose properties appear to be intimately linked to the magnetic state of the lattice. Despite extensive studies, the electronic character, mobility, and magnetic interactions of the exciton remain unresolved. Here we address these issues by measuring NiPS3 with ultra-high energy resolution resonant inelastic x-ray scattering (RIXS). We find that Hund's exchange interactions are primarily responsible for the energy of formation of the exciton. Measuring the dispersion of the Hund's exciton reveals that it propagates in a way that is analogous to a double-magnon. We trace this unique behavior to fundamental similarities between the NiPS3 exciton hopping and spin exchange processes, underlining the unique magnetic characteristics of this novel quasiparticle.
Collapse
Affiliation(s)
- W He
- Department of Condensed Matter Physics and Materials Science, Brookhaven National Laboratory, Upton, NY, 11973, USA.
| | - Y Shen
- Department of Condensed Matter Physics and Materials Science, Brookhaven National Laboratory, Upton, NY, 11973, USA
| | - K Wohlfeld
- Institute of Theoretical Physics, Faculty of Physics, University of Warsaw, Warsaw, PL-02093, Poland
| | - J Sears
- Department of Condensed Matter Physics and Materials Science, Brookhaven National Laboratory, Upton, NY, 11973, USA
| | - J Li
- National Synchrotron Light Source II, Brookhaven National Laboratory, Upton, NY, 11973, USA
| | - J Pelliciari
- National Synchrotron Light Source II, Brookhaven National Laboratory, Upton, NY, 11973, USA
| | - M Walicki
- Institute of Theoretical Physics, Faculty of Physics, University of Warsaw, Warsaw, PL-02093, Poland
| | - S Johnston
- Department of Physics and Astronomy, The University of Tennessee, Knoxville, TN, 37996, USA
- Institute of Advanced Materials and Manufacturing, The University of Tennessee, Knoxville, TN, 37996, USA
| | - E Baldini
- Department of Physics, The University of Texas at Austin, Austin, TX, 78712, USA
| | - V Bisogni
- National Synchrotron Light Source II, Brookhaven National Laboratory, Upton, NY, 11973, USA
| | - M Mitrano
- Department of Physics, Harvard University, Cambridge, MA, 02138, USA
| | - M P M Dean
- Department of Condensed Matter Physics and Materials Science, Brookhaven National Laboratory, Upton, NY, 11973, USA.
| |
Collapse
|
2
|
Grammatikos A, Moghaddas F, White P, Fox C, Johnston S, Tsiougkos N, Gompels M. The incidence of physician-diagnosed food allergy declines with age: A specialist UK centre experience. Clin Exp Allergy 2024; 54:143-144. [PMID: 37771188 DOI: 10.1111/cea.14405] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2023] [Revised: 09/05/2023] [Accepted: 09/19/2023] [Indexed: 09/30/2023]
Affiliation(s)
- Alexandros Grammatikos
- Bristol Immunology and Allergy Centre, Southmead Hospital, North Bristol NHS Trust, Bristol, UK
| | - Fiona Moghaddas
- Bristol Immunology and Allergy Centre, Southmead Hospital, North Bristol NHS Trust, Bristol, UK
| | - Paul White
- Department of Mathematics and Statistics, University of the West of England Bristol, Bristol, UK
| | - Catherine Fox
- Bristol Immunology and Allergy Centre, Southmead Hospital, North Bristol NHS Trust, Bristol, UK
| | - Sarah Johnston
- Bristol Immunology and Allergy Centre, Southmead Hospital, North Bristol NHS Trust, Bristol, UK
| | - Nikolaos Tsiougkos
- Bristol Immunology and Allergy Centre, Southmead Hospital, North Bristol NHS Trust, Bristol, UK
| | - Mark Gompels
- Bristol Immunology and Allergy Centre, Southmead Hospital, North Bristol NHS Trust, Bristol, UK
| |
Collapse
|
3
|
Grammatikos A, Thomas M, Johnston S, Moghaddas F, Albur M, Yong P, Buckland M, Grigoriadou S, Whyte AF, Herwadkar A, Gompels M. Chronic or recurrent Campylobacter enteritis in primary immunodeficiency: A UK national case-series and review of the literature. J Allergy Clin Immunol Pract 2023; 11:2948-2954.e4. [PMID: 37301434 DOI: 10.1016/j.jaip.2023.05.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/16/2022] [Revised: 05/15/2023] [Accepted: 05/31/2023] [Indexed: 06/12/2023]
Affiliation(s)
- Alexandros Grammatikos
- Bristol Immunology and Allergy Centre, Southmead Hospital, North Bristol NHS Trust, Bristol, United Kingdom.
| | - Moira Thomas
- Clinical Immunology Service, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
| | - Sarah Johnston
- Bristol Immunology and Allergy Centre, Southmead Hospital, North Bristol NHS Trust, Bristol, United Kingdom
| | - Fiona Moghaddas
- Bristol Immunology and Allergy Centre, Southmead Hospital, North Bristol NHS Trust, Bristol, United Kingdom
| | - Mahableshwar Albur
- Bristol Centre for Antimicrobial Research and Evaluation, North Bristol NHS Trust, Bristol, United Kingdom
| | - Patrick Yong
- Immunology Department, Frimley Park Hospital, Frimley Health NHS Trust, Frimley, United Kingdom
| | - Matthew Buckland
- Immunology Department, Barts and The London NHS Trust, London, United Kingdom
| | - Sofia Grigoriadou
- Immunology Department, Barts and The London NHS Trust, London, United Kingdom
| | - Andrew F Whyte
- Department of Allergy and Immunology, University Hospitals Plymouth NHS Trust, Derriford Hospital, Plymouth, United Kingdom
| | - Archana Herwadkar
- Immunology Department, Northern Care NHS Foundation Trust, Manchester, United Kingdom
| | - Mark Gompels
- Bristol Immunology and Allergy Centre, Southmead Hospital, North Bristol NHS Trust, Bristol, United Kingdom
| |
Collapse
|
4
|
Trip K, Wilson J, Ahuja A, Johnston S, Verkuyl M, Innis JA. Student Engagement With an Open Educational Resource on Gynecological Assessment. J Nurse Pract 2023. [DOI: 10.1016/j.nurpra.2022.104529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
5
|
Fabbris G, Meyers D, Shen Y, Bisogni V, Zhang J, Mitchell JF, Norman MR, Johnston S, Feng J, Chiuzbăian GS, Nicolaou A, Jaouen N, Dean MPM. Resonant inelastic x-ray scattering data for Ruddlesden-Popper and reduced Ruddlesden-Popper nickelates. Sci Data 2023; 10:174. [PMID: 36991033 PMCID: PMC10060392 DOI: 10.1038/s41597-023-02079-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2023] [Accepted: 03/16/2023] [Indexed: 03/31/2023] Open
Abstract
Ruddlesden-Popper and reduced Ruddlesden-Popper nickelates are intriguing candidates for mimicking the properties of high-temperature superconducting cuprates. The degree of similarity between these nickelates and cuprates has been the subject of considerable debate. Resonant inelastic x-ray scattering (RIXS) has played an important role in exploring their electronic and magnetic excitations, but these efforts have been stymied by inconsistencies between different samples and the lack of publicly available data for detailed comparison. To address this issue, we present open RIXS data on La4Ni3O10 and La4Ni3O8.
Collapse
Affiliation(s)
- G Fabbris
- Condensed Matter Physics and Materials Science Department, Brookhaven National Laboratory, Upton, New York, 11973, USA.
- Advanced Photon Source, Argonne National Laboratory, Lemont, Illinois, 60439, USA.
| | - D Meyers
- Condensed Matter Physics and Materials Science Department, Brookhaven National Laboratory, Upton, New York, 11973, USA
- Department of Physics, Oklahoma State University, Stillwater, Oklahoma, 74078, USA
| | - Y Shen
- Condensed Matter Physics and Materials Science Department, Brookhaven National Laboratory, Upton, New York, 11973, USA
| | - V Bisogni
- National Synchrotron Light Source II, Brookhaven National Laboratory, Upton, New York, 11973, USA
| | - J Zhang
- Materials Science Division, Argonne National Laboratory, Lemont, Illinois, 60439, USA
- Institute of Crystal Materials, Shandong University, Jinan, Shandong, 250100, China
| | - J F Mitchell
- Materials Science Division, Argonne National Laboratory, Lemont, Illinois, 60439, USA
| | - M R Norman
- Materials Science Division, Argonne National Laboratory, Lemont, Illinois, 60439, USA
| | - S Johnston
- Department of Physics and Astronomy, The University of Tennessee, Knoxville, Tennessee, 37966, USA
- Institute of Advanced Materials and Manufacturing, The University of Tennessee, Knoxville, Tennessee, 37996, USA
| | - J Feng
- Sorbonne Université, CNRS, Laboratoire de Chimie Physique-Matière et Rayonnement, 75005, Paris, France
- Institute of Advanced Science Facilities, Shenzhen, Guangdong, 518107, China
| | - G S Chiuzbăian
- Sorbonne Université, CNRS, Laboratoire de Chimie Physique-Matière et Rayonnement, 75005, Paris, France
- Synchrotron SOLEIL, L'Orme des Merisiers, Saint-Aubin, BP 48, 91192, Gif-sur-Yvette, France
| | - A Nicolaou
- Synchrotron SOLEIL, L'Orme des Merisiers, Saint-Aubin, BP 48, 91192, Gif-sur-Yvette, France
| | - N Jaouen
- Synchrotron SOLEIL, L'Orme des Merisiers, Saint-Aubin, BP 48, 91192, Gif-sur-Yvette, France
| | - M P M Dean
- Condensed Matter Physics and Materials Science Department, Brookhaven National Laboratory, Upton, New York, 11973, USA.
| |
Collapse
|
6
|
Grammatikos A, Moghaddas F, Reeve H, Johnston S, Gompels M, Albur M. Low circulating B cells in immunocompromised individuals are linked to poorer antibody responses to vaccines and a predisposition to viral infections. J Allergy Clin Immunol Glob 2023; 2:111-113. [PMID: 37780112 PMCID: PMC10509987 DOI: 10.1016/j.jacig.2022.07.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 04/07/2022] [Revised: 06/28/2022] [Accepted: 07/18/2022] [Indexed: 10/03/2023]
Abstract
Background B cells play an important role in protection against viral infections, not only through the production of antibodies but also through their ability to act as antigen-presenting cells and produce cytokines. Objectives To assess whether there is a link between low circulating B-cell counts and a predisposition to viral infections in immunocompromised individuals, we performed a retrospective cohort analysis at 2 National Health Service Clinical Immunology sites in England. Methods Eligible patients were adults who were either diagnosed with or under investigation for an immunodeficiency and had recorded circulating B-cell counts. Information on viral infections was collected by using the departmental, hospital, and laboratory electronic information systems. A generalized linear model was used to analyze the relationship between B-cell counts and relevant indices of viral infection while controlling for patient age, diagnosis group, and T-cell and natural killer cell counts. Results A total of 376 eligible patients were identified, 134 of whom had B-cell counts that were below the laboratory-defined refence range (<0.11 ×109/L). Patients with low numbers of circulating B cells had lower pretreatment immunoglobulin levels and poorer antibody responses to vaccines (Streptococcus pneumonia, Clostridium tetani, and Haemophilus influenzae type B). An increased number of chronic or recurrent (P = .001), severe or unusual (P = .001), and PCR-confirmed viral infections (P = .04) were recorded in these patients versus in those with normal numbers of circulating B cells. Conclusion Overall, there was a statistically significant association between low circulating B-cell counts and the incidence of clinically important viral infections in this patient cohort, even when controlling for relevant covariates. Clinicians caring for patients with immunodeficiency should be vigilant for these types of infections, particularly in patients with low peripheral B-cell counts. A prospective study will be required to confirm these findings.
Collapse
Affiliation(s)
- Alexandros Grammatikos
- Bristol Immunology and Allergy Centre, Southmead Hospital, North Bristol NHS Trust, Bristol, United Kingdom
| | - Fiona Moghaddas
- Bristol Immunology and Allergy Centre, Southmead Hospital, North Bristol NHS Trust, Bristol, United Kingdom
| | - Henry Reeve
- School of Mathematics, University of Bristol, Bristol, United Kingdom
| | - Sarah Johnston
- Bristol Immunology and Allergy Centre, Southmead Hospital, North Bristol NHS Trust, Bristol, United Kingdom
| | - Mark Gompels
- Bristol Immunology and Allergy Centre, Southmead Hospital, North Bristol NHS Trust, Bristol, United Kingdom
| | - Mahableshwar Albur
- Bristol Centre for Antimicrobial Research and Evaluation, North Bristol NHS Trust, Bristol, United Kingdom
| |
Collapse
|
7
|
Moghaddas F, Tsiougkos N, Grammatikos A, Bright PD, Johnston S, Gompels M. COVID-19 vaccine allergy advice and guidance: The experience of a UK tertiary referral centre. World Allergy Organ J 2023; 16:100740. [PMID: 36644019 PMCID: PMC9825055 DOI: 10.1016/j.waojou.2022.100740] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2022] [Revised: 12/07/2022] [Accepted: 12/11/2022] [Indexed: 01/09/2023] Open
Abstract
Objective The objective was to review COVID-19 vaccine allergy advice and guidance requests received and assess the impact of advice outcome on vaccination outcome. Design A retrospective analysis of requests for advice and guidance regarding COVID-19 vaccine allergy was completed using an electronic referral system from February 2021 to January 2022. Participants A total of 1265 independent patient requests for advice were received from primary care. Full vaccination information was available on 1210 patients who were included in the analysis. Main outcome measures We evaluated the specific outcome of request for advice (written advice versus allergy consultation), rate of vaccination, vaccination combinations, and tolerance of vaccination. Results Of the 1210 patients included, 959 (79%) were female. Eight hundred and ninety-six (74%) requests were managed with written advice only and of these 675 (75%) patients went on to be vaccinated. Overall, 891 (74%) of the population were vaccinated with 2 or more doses.Two hundred and nineteen patient consultations were undertaken with 109 (50%) prior to the first vaccination. Forty-nine (45%) consultations prior to vaccination were undertaken due to a label of anaphylaxis to vaccination in the past. Vaccination was recommended for all patients, and 78 (72%) of these received a first dose. Eight of these patients (10%) had symptoms within 1 h of vaccine administration.One hundred and ten (50%) consultations were undertaken for adverse reactions post COVID-19 vaccination, with 84 (76%) concerning immediate symptoms. Thirty patients (27%) who had a consultation had had adrenaline administered post vaccination. One patient had biopsy confirmed Stevens Johnson Syndrome and was referred to Dermatology. All others due for further doses (107 patients) were recommended to have subsequent doses with 49 (45%) offered the same vaccine. Eighty-nine patients had a vaccine administered post adverse reaction and 79 (88%) tolerated the dose.Skin testing and challenge to polyethylene glycol were negative in the 8 patients tested. Conclusions Over 1000 requests for advice and guidance were received during the review period, managed mainly with written advice. The overwhelming majority of requests for advice and consultations were for females, with equal distribution both pre- and post-COVID-19 vaccine administration. Vaccination was recommended in all but 1 patient (with biopsy confirmed Stevens Johnson Syndrome). Polyethylene glycol allergy was not confirmed in any patient, nor did any patient have confirmed anaphylaxis when the vaccine was administered under our supervision, suggesting that type 1 mediated hypersensitivity is uncommon even in this "high risk" population.
Collapse
|
8
|
Pattwell M, Eldridge L, Milton M, Jethwa J, Murphy J, Slavova-Boneva V, Kiely G, Cowan-Dickie S, Pessoa Silva M, Tomlins E, Crimmin J, McWhirter A, Roe J, Ashforth K, Grayer J, Henderson B, Stanley P, Mann L, Halsted A, Kano Y, McGinn M, Droney J, Mooney J, Bateman E, Wood J, Kipps E, Johnston S, Ashurst I, Ring A, Battisti N. Nutritional needs in older adults receiving systemic treatment for breast cancer: The Royal Marsden Senior Adult Oncology Programme experience. J Geriatr Oncol 2022. [DOI: 10.1016/s1879-4068(22)00350-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
9
|
Shields AM, Anantharachagan A, Arumugakani G, Baker K, Bahal S, Baxendale H, Bermingham W, Bhole M, Boules E, Bright P, Chopra C, Cliffe L, Cleave B, Dempster J, Devlin L, Dhalla F, Diwakar L, Drewe E, Duncan C, Dziadzio M, Elcombe S, Elkhalifa S, Gennery A, Ghanta H, Goddard S, Grigoriadou S, Hackett S, Hayman G, Herriot R, Herwadkar A, Huissoon A, Jain R, Jolles S, Johnston S, Khan S, Laffan J, Lane P, Leeman L, Lowe DM, Mahabir S, Lochlainn DJM, McDermott E, Misbah S, Moghaddas F, Morsi H, Murng S, Noorani S, O'Brien R, Patel S, Price A, Rahman T, Seneviratne S, Shrimpton A, Stroud C, Thomas M, Townsend K, Vaitla P, Verma N, Williams A, Burns SO, Savic S, Richter AG. Outcomes following SARS-CoV-2 infection in patients with primary and secondary immunodeficiency in the UK. Clin Exp Immunol 2022; 209:247-258. [PMID: 35641155 PMCID: PMC8807296 DOI: 10.1093/cei/uxac008] [Citation(s) in RCA: 19] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2021] [Revised: 12/16/2021] [Accepted: 01/25/2022] [Indexed: 12/29/2022] Open
Abstract
In March 2020, the United Kingdom Primary Immunodeficiency Network (UKPIN) established a registry of cases to collate the outcomes of individuals with PID and SID following SARS-CoV-2 infection and treatment. A total of 310 cases of SARS-CoV-2 infection in individuals with PID or SID have now been reported in the UK. The overall mortality within the cohort was 17.7% (n = 55/310). Individuals with CVID demonstrated an infection fatality rate (IFR) of 18.3% (n = 17/93), individuals with PID receiving IgRT had an IFR of 16.3% (n = 26/159) and individuals with SID, an IFR of 27.2% (n = 25/92). Individuals with PID and SID had higher inpatient mortality and died at a younger age than the general population. Increasing age, low pre-SARS-CoV-2 infection lymphocyte count and the presence of common co-morbidities increased the risk of mortality in PID. Access to specific COVID-19 treatments in this cohort was limited: only 22.9% (n = 33/144) of patients admitted to the hospital received dexamethasone, remdesivir, an anti-SARS-CoV-2 antibody-based therapeutic (e.g. REGN-COV2 or convalescent plasma) or tocilizumab as a monotherapy or in combination. Dexamethasone, remdesivir, and anti-SARS-CoV-2 antibody-based therapeutics appeared efficacious in PID and SID. Compared to the general population, individuals with PID or SID are at high risk of mortality following SARS-CoV-2 infection. Increasing age, low baseline lymphocyte count, and the presence of co-morbidities are additional risk factors for poor outcome in this cohort.
Collapse
Affiliation(s)
- Adrian M Shields
- Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, UK
| | | | - Gururaj Arumugakani
- Department of Clinical Immunology and Allergy, St James University Hospital, Leeds Teaching Hospital NHS Trust, Leeds, UK
| | - Kenneth Baker
- NIHR Newcastle Biomedical Research Centre, Newcastle University and Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
| | - Sameer Bahal
- Department of Immunology, Royal Free London NHS Foundation Trust, London, UK
| | | | | | - Malini Bhole
- The Dudley Group NHS Foundation Trust, Birmingham, UK
| | - Evon Boules
- Clinical Immunology and Allergy Department, Sheffield Teaching Hospitals NHS Foundation Trust, UK
| | - Philip Bright
- Clinical Immunology, North Bristol NHS Trust, Bristol, UK
| | - Charu Chopra
- Department of Haematology & Immunology, Royal Infirmary of Edinburgh, NHS Lothian, UK
| | - Lucy Cliffe
- Clinical Immunology and Allergy Department, Nottingham University Hospital NHS Trust, Nottingham, UK
| | - Betsy Cleave
- Clinical Immunology and Allergy Department, Nottingham University Hospital NHS Trust, Nottingham, UK
| | - John Dempster
- Specialist Allergy and Clinical Immunology, University College London Hospitals, London, UK
| | - Lisa Devlin
- Regional Immunology Service, The Royal Hospitals, Belfast, UK
| | - Fatima Dhalla
- Department of Clinical Immunology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | - Lavanya Diwakar
- Department of Immunology, Royal Stoke Hospital, Stoke-on-Trent, UK
| | - Elizabeth Drewe
- Clinical Immunology and Allergy Department, Nottingham University Hospital NHS Trust, Nottingham, UK
| | - Christopher Duncan
- Translational and Clinical Research Institute, Immunity and Inflammation Theme, Newcastle University, Newcastle upon Tyne, UK
| | | | - Suzanne Elcombe
- Regional Department of Clinical Immunology & Allergy, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, UK
| | - Shuayb Elkhalifa
- Immunology Department, Salford Royal NHS Foundation Trust, Manchester, UK
| | - Andrew Gennery
- Translational and Clinical Research Institute, Newcastle University, and Paediatric Stem Cell Transplant Unit, Great North Children's Hospital, Newcastle upon Tyne, UK
| | - Harichandrana Ghanta
- Department of Allergy and Clinical Immunology, University Hospital Southampton NHS Trust, University of Southampton, Southampton, UK
| | - Sarah Goddard
- Department of Immunology, Royal Stoke Hospital, Stoke-on-Trent, UK
| | - Sofia Grigoriadou
- Immunology Department, Royal London Hospital, Barts Health NHS Trust, London, UK
| | - Scott Hackett
- Paediatric Immunology Department, University Hospitals of Birmingham, Birmingham, UK
| | - Grant Hayman
- Clinical Immunology Service, South West London Immunodeficiency Centre, Epsom and St Helier University Hospital NHS Trust, London, UK
| | - Richard Herriot
- Immunology Department, Aberdeen Royal Infirmary, Aberdeen, UK
| | - Archana Herwadkar
- Immunology Department, Salford Royal NHS Foundation Trust, Manchester, UK
| | - Aarnoud Huissoon
- University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
| | - Rashmi Jain
- Department of Clinical Immunology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | - Stephen Jolles
- Immunodeficiency Centre for Wales, University Hospital of Wales, Heath Park, Cardiff, UK
| | - Sarah Johnston
- Clinical Immunology, North Bristol NHS Trust, Bristol, UK
| | - Sujoy Khan
- Hull University Teaching Hospitals NHS Trust, Hull, UK
| | - James Laffan
- Clinical Immunology Service, South West London Immunodeficiency Centre, Epsom and St Helier University Hospital NHS Trust, London, UK
| | - Peter Lane
- Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, UK
| | - Lucy Leeman
- University Hospitals Plymouth NHS Trust, Plymouth, UK
| | - David M Lowe
- Institute of Immunity and Transplantation, University College London, London, UK.,Department of Immunology, Royal Free London NHS Foundation Trust, London, UK
| | - Shanti Mahabir
- Clinical Immunology and Allergy Department, Leicester Royal Infirmary, Leicester, UK
| | | | - Elizabeth McDermott
- Clinical Immunology and Allergy Department, Nottingham University Hospital NHS Trust, Nottingham, UK
| | - Siraj Misbah
- Department of Clinical Immunology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | | | - Hadeil Morsi
- Department of Clinical Immunology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | - Sai Murng
- Clinical Immunology Service, South West London Immunodeficiency Centre, Epsom and St Helier University Hospital NHS Trust, London, UK
| | - Sadia Noorani
- Clinical Immunology Department, Sandwell & West Birmingham Hospitals NHS Trust, Birmingham, UK
| | - Rachael O'Brien
- Department of Clinical Immunology, Frimley Park Hospital, Frimley, Surrey, UK
| | - Smita Patel
- Department of Clinical Immunology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | - Arthur Price
- Clinical Immunology and Allergy Department, Leicester Royal Infirmary, Leicester, UK
| | - Tasneem Rahman
- Clinical Immunology Service, South West London Immunodeficiency Centre, Epsom and St Helier University Hospital NHS Trust, London, UK
| | | | - Anna Shrimpton
- Clinical Immunology and Allergy Department, Sheffield Teaching Hospitals NHS Foundation Trust, UK
| | - Catherine Stroud
- Regional Department of Clinical Immunology & Allergy, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, UK
| | - Moira Thomas
- Clinical Immunology Service, NHS Greater Glasgow and Clyde, Glasgow, UK
| | - Katie Townsend
- Clinical Immunology Service, South West London Immunodeficiency Centre, Epsom and St Helier University Hospital NHS Trust, London, UK
| | - Prashantha Vaitla
- Clinical Immunology and Allergy Department, Nottingham University Hospital NHS Trust, Nottingham, UK
| | - Nisha Verma
- Institute of Immunity and Transplantation, University College London, London, UK
| | - Anthony Williams
- Department of Allergy and Clinical Immunology, University Hospital Southampton NHS Trust, University of Southampton, Southampton, UK
| | - Siobhan O Burns
- Institute of Immunity and Transplantation, University College London, London, UK.,Department of Immunology, Royal Free London NHS Foundation Trust, London, UK
| | - Sinisa Savic
- Department of Clinical Immunology and Allergy, St James University Hospital, Leeds Teaching Hospital NHS Trust, Leeds, UK
| | - Alex G Richter
- Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, UK
| |
Collapse
|
10
|
Adhikari D, Albataineh H, Androic D, Aniol KA, Armstrong DS, Averett T, Ayerbe Gayoso C, Barcus SK, Bellini V, Beminiwattha RS, Benesch JF, Bhatt H, Bhatta Pathak D, Bhetuwal D, Blaikie B, Boyd J, Campagna Q, Camsonne A, Cates GD, Chen Y, Clarke C, Cornejo JC, Covrig Dusa S, Dalton MM, Datta P, Deshpande A, Dutta D, Feldman C, Fuchey E, Gal C, Gaskell D, Gautam T, Gericke M, Ghosh C, Halilovic I, Hansen JO, Hassan O, Hauenstein F, Henry W, Horowitz CJ, Jantzi C, Jian S, Johnston S, Jones DC, Kakkar S, Katugampola S, Keppel C, King PM, King DE, Kumar KS, Kutz T, Lashley-Colthirst N, Leverick G, Liu H, Liyanage N, Mammei J, Mammei R, McCaughan M, McNulty D, Meekins D, Metts C, Michaels R, Mihovilovic M, Mondal MM, Napolitano J, Narayan A, Nikolaev D, Owen V, Palatchi C, Pan J, Pandey B, Park S, Paschke KD, Petrusky M, Pitt ML, Premathilake S, Quinn B, Radloff R, Rahman S, Rashad MNH, Rathnayake A, Reed BT, Reimer PE, Richards R, Riordan S, Roblin YR, Seeds S, Shahinyan A, Souder P, Thiel M, Tian Y, Urciuoli GM, Wertz EW, Wojtsekhowski B, Yale B, Ye T, Yoon A, Xiong W, Zec A, Zhang W, Zhang J, Zheng X. Precision Determination of the Neutral Weak Form Factor of ^{48}Ca. Phys Rev Lett 2022; 129:042501. [PMID: 35939025 DOI: 10.1103/physrevlett.129.042501] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/23/2022] [Revised: 06/15/2022] [Accepted: 06/16/2022] [Indexed: 06/15/2023]
Abstract
We report a precise measurement of the parity-violating (PV) asymmetry A_{PV} in the elastic scattering of longitudinally polarized electrons from ^{48}Ca. We measure A_{PV}=2668±106(stat)±40(syst) parts per billion, leading to an extraction of the neutral weak form factor F_{W}(q=0.8733 fm^{-1})=0.1304±0.0052(stat)±0.0020(syst) and the charge minus the weak form factor F_{ch}-F_{W}=0.0277±0.0055. The resulting neutron skin thickness R_{n}-R_{p}=0.121±0.026(exp)±0.024(model) fm is relatively thin yet consistent with many model calculations. The combined CREX and PREX results will have implications for future energy density functional calculations and on the density dependence of the symmetry energy of nuclear matter.
Collapse
Affiliation(s)
- D Adhikari
- Idaho State University, Pocatello, Idaho 83209, USA
| | - H Albataineh
- Texas A & M University-Kingsville, Kingsville, Texas 78363, USA
| | - D Androic
- University of Zagreb, Faculty of Science, Zagreb, HR 10002, Croatia
| | - K A Aniol
- California State University, Los Angeles, Los Angeles, California 90032, USA
| | | | - T Averett
- William and Mary, Williamsburg, Virginia 23185, USA
| | | | - S K Barcus
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - V Bellini
- Istituto Nazionale di Fisica Nucleare, Sezione di Catania, 95123 Catania, Italy
| | | | - J F Benesch
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - H Bhatt
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | | | - D Bhetuwal
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - B Blaikie
- University of Manitoba, Winnipeg, Manitoba R3T2N2, Canada
| | - J Boyd
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - Q Campagna
- William and Mary, Williamsburg, Virginia 23185, USA
| | - A Camsonne
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - G D Cates
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - Y Chen
- Louisiana Tech University, Ruston, Louisiana 71272, USA
| | - C Clarke
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
| | - J C Cornejo
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - S Covrig Dusa
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M M Dalton
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - P Datta
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - A Deshpande
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
- Center for Frontiers in Nuclear Science, Stony Brook, New York 11794, USA
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - D Dutta
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - C Feldman
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
- Institute for Advanced Computational Science, Stony Brook, New York 11794, USA
| | - E Fuchey
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - C Gal
- Mississippi State University, Mississippi State, Mississippi 39762, USA
- University of Virginia, Charlottesville, Virginia 22904, USA
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
- Center for Frontiers in Nuclear Science, Stony Brook, New York 11794, USA
| | - D Gaskell
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - T Gautam
- Hampton University, Hampton, Virginia 23668, USA
| | - M Gericke
- University of Manitoba, Winnipeg, Manitoba R3T2N2, Canada
| | - C Ghosh
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
- University of Massachusetts Amherst, Amherst, Massachusetts 01003, USA
| | - I Halilovic
- University of Manitoba, Winnipeg, Manitoba R3T2N2, Canada
| | - J-O Hansen
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - O Hassan
- University of Manitoba, Winnipeg, Manitoba R3T2N2, Canada
| | - F Hauenstein
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - W Henry
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - C J Horowitz
- Indiana University, Bloomington, Indiana 47405, USA
| | - C Jantzi
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - S Jian
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - S Johnston
- University of Massachusetts Amherst, Amherst, Massachusetts 01003, USA
| | - D C Jones
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - S Kakkar
- University of Manitoba, Winnipeg, Manitoba R3T2N2, Canada
| | - S Katugampola
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - C Keppel
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - P M King
- Ohio University, Athens, Ohio 45701, USA
| | - D E King
- Temple University, Philadelphia, Pennsylvania 19122, USA
- Syracuse University, Syracuse, New York 13244, USA
| | - K S Kumar
- University of Massachusetts Amherst, Amherst, Massachusetts 01003, USA
| | - T Kutz
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
| | | | - G Leverick
- University of Manitoba, Winnipeg, Manitoba R3T2N2, Canada
| | - H Liu
- University of Massachusetts Amherst, Amherst, Massachusetts 01003, USA
| | - N Liyanage
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - J Mammei
- University of Manitoba, Winnipeg, Manitoba R3T2N2, Canada
| | - R Mammei
- University of Winnipeg, Winnipeg, Manitoba R3B2E9, Canada
| | - M McCaughan
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - D McNulty
- Idaho State University, Pocatello, Idaho 83209, USA
| | - D Meekins
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - C Metts
- William and Mary, Williamsburg, Virginia 23185, USA
| | - R Michaels
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M Mihovilovic
- Jožef Stefan Institute, SI-1000 Ljubljana, Slovenia
- Faculty of Mathematics and Physics, University of Ljubljana, SI-1000 Ljubljana, Slovenia
| | - M M Mondal
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
- Center for Frontiers in Nuclear Science, Stony Brook, New York 11794, USA
| | - J Napolitano
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - A Narayan
- Veer Kunwar Singh University, Ara, Bihar 802301, India
| | - D Nikolaev
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - V Owen
- William and Mary, Williamsburg, Virginia 23185, USA
| | - C Palatchi
- University of Virginia, Charlottesville, Virginia 22904, USA
- Center for Frontiers in Nuclear Science, Stony Brook, New York 11794, USA
| | - J Pan
- University of Manitoba, Winnipeg, Manitoba R3T2N2, Canada
| | - B Pandey
- Hampton University, Hampton, Virginia 23668, USA
| | - S Park
- Mississippi State University, Mississippi State, Mississippi 39762, USA
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
| | - K D Paschke
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - M Petrusky
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
| | - M L Pitt
- Virginia Tech, Blacksburg, Virginia 24061, USA
| | - S Premathilake
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - B Quinn
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - R Radloff
- Ohio University, Athens, Ohio 45701, USA
| | - S Rahman
- University of Manitoba, Winnipeg, Manitoba R3T2N2, Canada
| | - M N H Rashad
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - A Rathnayake
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - B T Reed
- Indiana University, Bloomington, Indiana 47405, USA
| | - P E Reimer
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - R Richards
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
| | - S Riordan
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - Y R Roblin
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S Seeds
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - A Shahinyan
- A. I. Alikhanyan National Science Laboratory (Yerevan Physics Institute), Yerevan 0036, Armenia
| | - P Souder
- Syracuse University, Syracuse, New York 13244, USA
| | - M Thiel
- Institut für Kernphysik, Johannes Gutenberg-Universität, Mainz 55122, Germany
| | - Y Tian
- Syracuse University, Syracuse, New York 13244, USA
| | | | - E W Wertz
- William and Mary, Williamsburg, Virginia 23185, USA
| | - B Wojtsekhowski
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - B Yale
- William and Mary, Williamsburg, Virginia 23185, USA
| | - T Ye
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
| | - A Yoon
- Christopher Newport University, Newport News, Virginia 23606, USA
| | - W Xiong
- Syracuse University, Syracuse, New York 13244, USA
- Shandong University, Qingdao, Shandong 266237, China
| | - A Zec
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - W Zhang
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
| | - J Zhang
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
- Center for Frontiers in Nuclear Science, Stony Brook, New York 11794, USA
- Shandong University, Qingdao, Shandong 266237, China
| | - X Zheng
- University of Virginia, Charlottesville, Virginia 22904, USA
| |
Collapse
|
11
|
Shields AM, Faustini SE, Hill HJ, Al-Taei S, Tanner C, Ashford F, Workman S, Moreira F, Verma N, Wagg H, Heritage G, Campton N, Stamataki Z, Klenerman P, Thaventhiran JED, Goddard S, Johnston S, Huissoon A, Bethune C, Elcombe S, Lowe DM, Patel SY, Savic S, Burns SO, Richter AG. SARS-CoV-2 Vaccine Responses in Individuals with Antibody Deficiency: Findings from the COV-AD Study. J Clin Immunol 2022; 42:923-934. [PMID: 35420363 PMCID: PMC9008380 DOI: 10.1007/s10875-022-01231-7] [Citation(s) in RCA: 27] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2021] [Accepted: 02/10/2022] [Indexed: 12/04/2022]
Abstract
BACKGROUND Vaccination prevents severe morbidity and mortality from COVID-19 in the general population. The immunogenicity and efficacy of SARS-CoV-2 vaccines in patients with antibody deficiency is poorly understood. OBJECTIVES COVID-19 in patients with antibody deficiency (COV-AD) is a multi-site UK study that aims to determine the immune response to SARS-CoV-2 infection and vaccination in patients with primary or secondary antibody deficiency, a population that suffers from severe and recurrent infection and does not respond well to vaccination. METHODS Individuals on immunoglobulin replacement therapy or with an IgG less than 4 g/L receiving antibiotic prophylaxis were recruited from April 2021. Serological and cellular responses were determined using ELISA, live-virus neutralisation and interferon gamma release assays. SARS-CoV-2 infection and clearance were determined by PCR from serial nasopharyngeal swabs. RESULTS A total of 5.6% (n = 320) of the cohort reported prior SARS-CoV-2 infection, but only 0.3% remained PCR positive on study entry. Seropositivity, following two doses of SARS-CoV-2 vaccination, was 54.8% (n = 168) compared with 100% of healthy controls (n = 205). The magnitude of the antibody response and its neutralising capacity were both significantly reduced compared to controls. Participants vaccinated with the Pfizer/BioNTech vaccine were more likely to be seropositive (65.7% vs. 48.0%, p = 0.03) and have higher antibody levels compared with the AstraZeneca vaccine (IgGAM ratio 3.73 vs. 2.39, p = 0.0003). T cell responses post vaccination was demonstrable in 46.2% of participants and were associated with better antibody responses but there was no difference between the two vaccines. Eleven vaccine-breakthrough infections have occurred to date, 10 of them in recipients of the AstraZeneca vaccine. CONCLUSION SARS-CoV-2 vaccines demonstrate reduced immunogenicity in patients with antibody deficiency with evidence of vaccine breakthrough infection.
Collapse
Affiliation(s)
- Adrian M Shields
- Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
- University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
| | - Sian E Faustini
- Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK
| | - Harriet J Hill
- Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK
| | - Saly Al-Taei
- Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK
| | - Chloe Tanner
- Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK
| | - Fiona Ashford
- Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK
| | - Sarita Workman
- Department of Immunology, Royal Free London NHS Foundation Trust, London, UK
| | - Fernando Moreira
- Department of Immunology, Royal Free London NHS Foundation Trust, London, UK
| | - Nisha Verma
- Department of Immunology, Royal Free London NHS Foundation Trust, London, UK
| | - Hollie Wagg
- Institute of Translational Medicine, University of Birmingham, Birmingham, UK
| | - Gail Heritage
- Institute of Translational Medicine, University of Birmingham, Birmingham, UK
| | - Naomi Campton
- Institute of Translational Medicine, University of Birmingham, Birmingham, UK
| | - Zania Stamataki
- Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK
| | - Paul Klenerman
- Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - James E D Thaventhiran
- Medical Research Council Toxicology Unit, University of Cambridge, Gleeson Building, Tennis Court Road, Cambridge, CB2 1QW, UK
| | - Sarah Goddard
- Department of Clinical Immunology, University Hospitals North Midlands, Stoke-on-Trent, UK
| | - Sarah Johnston
- Department of Clinical Immunology, North Bristol NHS Trust, Bristol, UK
| | - Aarnoud Huissoon
- University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
| | - Claire Bethune
- Department of Allergy and Clinical Immunology, University Hospitals Plymouth NHS Trust, Plymouth, UK
| | - Suzanne Elcombe
- Department of Allergy and Clinical Immunology, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK
| | - David M Lowe
- Department of Immunology, Royal Free London NHS Foundation Trust, London, UK
- Institute of Immunity and Transplantation, University College London, London, UK
| | - Smita Y Patel
- Nuffield Department of Medicine, University of Oxford, Oxford, UK
- NIHR BRC Oxford Biomedical Centre, University of Oxford, Oxford, UK
| | - Sinisa Savic
- Department of Allergy and Clinical Immunology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - Siobhan O Burns
- Department of Immunology, Royal Free London NHS Foundation Trust, London, UK.
- Institute of Immunity and Transplantation, University College London, London, UK.
| | - Alex G Richter
- Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
- University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
| |
Collapse
|
12
|
Shields AM, Faustini SE, Hill HJ, Al-Taei S, Tanner C, Ashford F, Workman S, Moreira F, Verma N, Wagg H, Heritage G, Campton N, Stamataki Z, Drayson MT, Klenerman P, Thaventhiran JED, Elkhalifa S, Goddard S, Johnston S, Huissoon A, Bethune C, Elcombe S, Lowe DM, Patel SY, Savic S, Richter AG, Burns SO. Increased Seroprevalence and Improved Antibody Responses Following Third Primary SARS-CoV-2 Immunisation: An Update From the COV-AD Study. Front Immunol 2022; 13:912571. [PMID: 35720400 PMCID: PMC9201027 DOI: 10.3389/fimmu.2022.912571] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2022] [Accepted: 05/06/2022] [Indexed: 11/29/2022] Open
Abstract
Background Patients with primary and secondary antibody deficiency are vulnerable to COVID-19 and demonstrate diminished responses following two-dose SARS-CoV-2 vaccine schedules. Third primary vaccinations have been deployed to enhance their humoral and cellular immunity. Objectives To determine the immunogenicity of the third primary SARS-CoV-2 immunisation in a heterogeneous cohort of patients with antibody deficiency. Methods Participants enrolled in the COV-AD study were sampled before and after their third vaccine dose. Serological and cellular responses were determined using ELISA, live-virus neutralisation and ELISPOT assays. Results Following a two-dose schedule, 100% of healthy controls mounted a serological response to SARS-CoV-2 vaccination, however, 38.6% of individuals with antibody deficiency remained seronegative. A third primary SARS-CoV-2 vaccine significantly increased anti-spike glycoprotein antibody seroprevalence from 61.4% to 76.0%, the magnitude of the antibody response, its neutralising capacity and induced seroconversion in individuals who were seronegative after two vaccine doses. Vaccine-induced serological responses were broadly cross-reactive against the SARS-CoV-2 B.1.1.529 variant of concern, however, seroprevalence and antibody levels remained significantly lower than healthy controls. No differences in serological responses were observed between individuals who received AstraZeneca ChAdOx1 nCoV-19 and Pfizer BioNTech 162b2 during their initial two-dose vaccine schedule. SARS-CoV-2 infection-naive participants who had received a heterologous vaccine as a third dose were significantly more likely to have a detectable T cell response following their third vaccine dose (61.5% vs 11.1%). Conclusion These data support the widespread use of third primary immunisations to enhance humoral immunity against SARS-CoV-2 in individuals with antibody deficiency.
Collapse
Affiliation(s)
- Adrian M. Shields
- Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom
- Department of Clinical Immunology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
| | - Sian E. Faustini
- Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom
| | - Harriet J. Hill
- Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom
| | - Saly Al-Taei
- Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom
| | - Chloe Tanner
- Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom
| | - Fiona Ashford
- Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom
| | - Sarita Workman
- Department of Immunology, Royal Free London NHS Foundation Trust, London, United Kingdom
| | - Fernando Moreira
- Department of Immunology, Royal Free London NHS Foundation Trust, London, United Kingdom
| | - Nisha Verma
- Department of Immunology, Royal Free London NHS Foundation Trust, London, United Kingdom
| | - Hollie Wagg
- Institute of Translational Medicine, University of Birmingham, Birmingham, United Kingdom
| | - Gail Heritage
- Institute of Translational Medicine, University of Birmingham, Birmingham, United Kingdom
| | - Naomi Campton
- Institute of Translational Medicine, University of Birmingham, Birmingham, United Kingdom
| | - Zania Stamataki
- Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom
| | - Mark T. Drayson
- Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom
| | - Paul Klenerman
- Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
| | | | - Shuayb Elkhalifa
- Department of Immunology, Salford Royal NHS Foundation Trust, Salford, United Kingdom
| | - Sarah Goddard
- Department of Clinical Immunology, University Hospitals North Midlands, Stoke-on-Trent, United Kingdom
| | - Sarah Johnston
- Department of Clinical Immunology, North Bristol NHS Trust, Bristol, United Kingdom
| | - Aarnoud Huissoon
- Department of Clinical Immunology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
| | - Claire Bethune
- Department of Allergy and Clinical Immunology, University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom
| | - Suzanne Elcombe
- Department of Allergy and Clinical Immunology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom
| | - David M. Lowe
- Department of Immunology, Royal Free London NHS Foundation Trust, London, United Kingdom
- Institute of Immunity and Transplantation, University College London, London, United Kingdom
| | - Smita Y. Patel
- Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
- National Institute for Health and Care Research (NIHR) Biomedical Research Centre (BRC) Oxford Biomedical Centre, University of Oxford, Oxford, United Kingdom
| | - Sinisa Savic
- Department of Allergy and Clinical Immunology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
| | - Alex G. Richter
- Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom
- Department of Clinical Immunology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
| | - Siobhan O. Burns
- Department of Immunology, Royal Free London NHS Foundation Trust, London, United Kingdom
- Institute of Immunity and Transplantation, University College London, London, United Kingdom
| |
Collapse
|
13
|
Akhtar KH, Johnston S, Zhao YD, Amil F, Ford L, Lindenfeld J, Dasari TW. Meta-analysis Analyzing the Effect of Therapies on 6-Minute Walk Distance in Heart Failure With Reduced Ejection Fraction. Am J Cardiol 2022; 178:72-79. [DOI: 10.1016/j.amjcard.2022.05.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/16/2022] [Revised: 05/15/2022] [Accepted: 05/17/2022] [Indexed: 11/30/2022]
|
14
|
Porrett P, Gonzalez MV, Garifallou J, Wright ED, Lucander ACK, Bell MJ, Tyson K, Smiler J, Mafra F, Da Silva RP, Johnston S, Naziruddin B, Testa G, Johannesson L, George J, Freud A, O’Neill K. Aberrant survival of uterine natural killer subsets in uterus transplant recipients. The Journal of Immunology 2022. [DOI: 10.4049/jimmunol.208.supp.171.06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Abstract
Uterine natural killer cells (uNKs) are critical mediators of pregnancy success, but how aberrancies in uNK survival or differentiation underpin pregnancy complications is unknown. To improve our understanding of normal and abnormal uNK biology, we studied 1) uNKs in uterus transplant (UTx) recipients at high risk for pregnancy complications and 2) uNK survival after exposure to pharmacologic immunosuppression in vitro. To address the first question, we analyzed uNKs isolated from endometrial biopsies of healthy controls (n=3) or UTx recipients (n=5) using scRNA-seq. In healthy controls, CD103-expressing uNK3 cells were the dominant uNK subset (30% of all uNK cells). In contrast, uNK1 cells were the most frequent (30%) in the majority of UTx recipients. This dominance of uNK1 cells in UTx recipients did not appear to arise only from loss of uNK3 cells, as the uNK1 transcriptional signature was abnormally upregulated in immature proliferating uNKs. Next, we used multiparameter flow cytometry to study single-cell suspensions of whole endometrium from deceased organ donors (n=4) that were cultured for one week with or without the calcineurin inhibitor FK506. Although FK506 significantly impaired the survival of CD103+ uNK3 cells in vitro, there was no evidence of uNK1 enhancement. Instead, FK506 appeared to selectively deplete CD39+ cells – a marker currently used to identify human decidual NK1 cells. Altogether, these results demonstrate that the distribution of uNK subsets is often altered in UTx recipients, and that FK506 can impact the survival of specific uNK subsets. Identification of the additional factors which impact uNK differentiation and survival will be necessary to understand the genesis of pregnancy complications.
Supported by NIH/NIAID (R01 AI 145905) University of Pennsylvania Institute for Immunology
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | - Sarah Johnston
- 5Perelman School of Medicine, University of Pennsylvania
| | | | | | | | | | | | | |
Collapse
|
15
|
Adhikari D, Albataineh H, Androic D, Aniol K, Armstrong DS, Averett T, Ayerbe Gayoso C, Barcus S, Bellini V, Beminiwattha RS, Benesch JF, Bhatt H, Bhatta Pathak D, Bhetuwal D, Blaikie B, Boyd J, Campagna Q, Camsonne A, Cates GD, Chen Y, Clarke C, Cornejo JC, Covrig Dusa S, Dalton MM, Datta P, Deshpande A, Dutta D, Feldman C, Fuchey E, Gal C, Gaskell D, Gautam T, Gericke M, Ghosh C, Halilovic I, Hansen JO, Hauenstein F, Henry W, Horowitz CJ, Jantzi C, Jian S, Johnston S, Jones DC, Karki B, Kakkar S, Katugampola S, Keppel CE, King PM, King DE, Knauss M, Kumar KS, Kutz T, Lashley-Colthirst N, Leverick G, Liu H, Liyange N, Malace S, Mammei J, Mammei R, McCaughan M, McNulty D, Meekins D, Metts C, Michaels R, Mihovilovic M, Mondal MM, Napolitano J, Nikolaev D, Rashad MNH, Owen V, Palatchi C, Pan J, Pandey B, Park S, Paschke KD, Petrusky M, Pitt ML, Premathilake S, Puckett AJR, Quinn B, Radloff R, Rahman S, Rathnayake A, Reed BT, Reimer PE, Richards R, Riordan S, Roblin Y, Seeds S, Shahinyan A, Souder PA, Tang L, Thiel M, Tian Y, Urciuoli GM, Wertz EW, Wojtsekhowski B, Xiong W, Yale B, Ye T, Zec A, Zhang W, Zhang J, Zheng X. New Measurements of the Beam-Normal Single Spin Asymmetry in Elastic Electron Scattering over a Range of Spin-0 Nuclei. Phys Rev Lett 2022; 128:142501. [PMID: 35476486 DOI: 10.1103/physrevlett.128.142501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/09/2021] [Revised: 01/31/2022] [Accepted: 02/04/2022] [Indexed: 06/14/2023]
Abstract
We report precision determinations of the beam-normal single spin asymmetries (A_{n}) in the elastic scattering of 0.95 and 2.18 GeV electrons off ^{12}C, ^{40}Ca, ^{48}Ca, and ^{208}Pb at very forward angles where the most detailed theoretical calculations have been performed. The first measurements of A_{n} for ^{40}Ca and ^{48}Ca are found to be similar to that of ^{12}C, consistent with expectations and thus demonstrating the validity of theoretical calculations for nuclei with Z≤20. We also report A_{n} for ^{208}Pb at two new momentum transfers (Q^{2}) extending the previous measurement. Our new data confirm the surprising result previously reported, with all three data points showing significant disagreement with the results from the Z≤20 nuclei. These data confirm our basic understanding of the underlying dynamics that govern A_{n} for nuclei containing ≲50 nucleons, but point to the need for further investigation to understand the unusual A_{n} behavior discovered for scattering off ^{208}Pb.
Collapse
Affiliation(s)
- D Adhikari
- Idaho State University, Pocatello, Idaho 83209, USA
| | - H Albataineh
- Texas A & M University - Kingsville, Kingsville, Texas 78363, USA
| | - D Androic
- University of Zagreb, Faculty of Science, Zagreb HR 10002, Croatia
| | - K Aniol
- California State University, Los Angeles, Los Angeles, California 90032, USA
| | | | - T Averett
- William & Mary, Williamsburg, Virginia 23185, USA
| | | | - S Barcus
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - V Bellini
- Istituto Nazionale di Fisica Nucleare, Sezione di Catania, 95123 Catania, Italy
| | | | - J F Benesch
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - H Bhatt
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | | | - D Bhetuwal
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - B Blaikie
- University of Manitoba, Winnipeg, Manitoba R3T2N2, Canada
| | - J Boyd
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - Q Campagna
- William & Mary, Williamsburg, Virginia 23185, USA
| | - A Camsonne
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - G D Cates
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - Y Chen
- Louisiana Tech University, Ruston, Louisiana 71272, USA
| | - C Clarke
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
| | - J C Cornejo
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - S Covrig Dusa
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M M Dalton
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - P Datta
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - A Deshpande
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
- Center for Frontiers in Nuclear Science, Stony Brook, New York 11794, USA
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - D Dutta
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - C Feldman
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
- Institute for Advanced Computational Science, Stony Brook, New York 11794, USA
| | - E Fuchey
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - C Gal
- Mississippi State University, Mississippi State, Mississippi 39762, USA
- University of Virginia, Charlottesville, Virginia 22904, USA
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
- Center for Frontiers in Nuclear Science, Stony Brook, New York 11794, USA
| | - D Gaskell
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - T Gautam
- Hampton University, Hampton, Virginia 23668, USA
| | - M Gericke
- University of Manitoba, Winnipeg, Manitoba R3T2N2, Canada
| | - C Ghosh
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
- University of Massachusetts Amherst, Amherst, Massachusetts 01003, USA
| | - I Halilovic
- University of Manitoba, Winnipeg, Manitoba R3T2N2, Canada
| | - J-O Hansen
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - F Hauenstein
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - W Henry
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - C J Horowitz
- Indiana University, Bloomington, Indiana 47405, USA
| | - C Jantzi
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - S Jian
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - S Johnston
- University of Massachusetts Amherst, Amherst, Massachusetts 01003, USA
| | - D C Jones
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - B Karki
- Ohio University, Athens, Ohio 45701, USA
| | - S Kakkar
- University of Manitoba, Winnipeg, Manitoba R3T2N2, Canada
| | - S Katugampola
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - C E Keppel
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - P M King
- Ohio University, Athens, Ohio 45701, USA
| | - D E King
- Syracuse University, Syracuse, New York 13244, USA
| | - M Knauss
- Duquesne University, 600 Forbes Avenue, Pittsburgh, Pennsylvania 15282, USA
| | - K S Kumar
- University of Massachusetts Amherst, Amherst, Massachusetts 01003, USA
| | - T Kutz
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
| | | | - G Leverick
- University of Manitoba, Winnipeg, Manitoba R3T2N2, Canada
| | - H Liu
- University of Massachusetts Amherst, Amherst, Massachusetts 01003, USA
| | - N Liyange
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - S Malace
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - J Mammei
- University of Manitoba, Winnipeg, Manitoba R3T2N2, Canada
| | - R Mammei
- University of Winnipeg, Winnipeg, Manitoba R3B2E9, Canada
| | - M McCaughan
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - D McNulty
- Idaho State University, Pocatello, Idaho 83209, USA
| | - D Meekins
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - C Metts
- William & Mary, Williamsburg, Virginia 23185, USA
| | - R Michaels
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M Mihovilovic
- Jôzef Stefan Institute, Ljubljana 1000, Slovenia
- Faculty of Mathematics and Physics, University of Ljubljana, Ljubljana 1000, Slovenia
| | - M M Mondal
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
- Center for Frontiers in Nuclear Science, Stony Brook, New York 11794, USA
| | - J Napolitano
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - D Nikolaev
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - M N H Rashad
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - V Owen
- William & Mary, Williamsburg, Virginia 23185, USA
| | - C Palatchi
- University of Virginia, Charlottesville, Virginia 22904, USA
- Center for Frontiers in Nuclear Science, Stony Brook, New York 11794, USA
| | - J Pan
- University of Manitoba, Winnipeg, Manitoba R3T2N2, Canada
| | - B Pandey
- Hampton University, Hampton, Virginia 23668, USA
| | - S Park
- Mississippi State University, Mississippi State, Mississippi 39762, USA
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
| | - K D Paschke
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - M Petrusky
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
- University of Colorado Boulder, Boulder, Colorado 80309, USA
| | - M L Pitt
- Virginia Tech, Blacksburg, Virginia 24061, USA
| | - S Premathilake
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - A J R Puckett
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - B Quinn
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - R Radloff
- Ohio University, Athens, Ohio 45701, USA
| | - S Rahman
- University of Manitoba, Winnipeg, Manitoba R3T2N2, Canada
| | - A Rathnayake
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - B T Reed
- Indiana University, Bloomington, Indiana 47405, USA
| | - P E Reimer
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - R Richards
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
| | - S Riordan
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - Y Roblin
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S Seeds
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - A Shahinyan
- A. I. Alikhanyan National Science Laboratory (Yerevan Physics Institute), Yerevan 0036, Armenia
| | - P A Souder
- Syracuse University, Syracuse, New York 13244, USA
| | - L Tang
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
- Hampton University, Hampton, Virginia 23668, USA
| | - M Thiel
- Institut für Kernphysik, Johannes Gutenberg-Universität, Mainz 55099, Germany
| | - Y Tian
- Syracuse University, Syracuse, New York 13244, USA
| | | | - E W Wertz
- William & Mary, Williamsburg, Virginia 23185, USA
| | - B Wojtsekhowski
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - W Xiong
- Syracuse University, Syracuse, New York 13244, USA
| | - B Yale
- William & Mary, Williamsburg, Virginia 23185, USA
| | - T Ye
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
| | - A Zec
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - W Zhang
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
| | - J Zhang
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
- Center for Frontiers in Nuclear Science, Stony Brook, New York 11794, USA
- Shandong University, Qingdao, Shandong 266237, China
| | - X Zheng
- University of Virginia, Charlottesville, Virginia 22904, USA
| |
Collapse
|
16
|
Rugo HS, O'Shaughnessy J, Boyle F, Toi M, Broom R, Blancas I, Gumus M, Yamashita T, Im YH, Rastogi P, Zagouri F, Song C, Campone M, San Antonio B, Shahir A, Hulstijn M, Brown J, Zimmermann A, Wei R, Johnston S, Reinisch M, Tolaney SM. Adjuvant Abemaciclib Combined with Endocrine Therapy for High Risk Early Breast Cancer: Safety and Patient-Reported Outcomes From the monarchE Study. Ann Oncol 2022; 33:616-627. [PMID: 35337972 DOI: 10.1016/j.annonc.2022.03.006] [Citation(s) in RCA: 36] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2022] [Revised: 03/07/2022] [Accepted: 03/11/2022] [Indexed: 11/30/2022] Open
Abstract
BACKGROUND In monarchE, abemaciclib plus endocrine therapy (ET) as adjuvant treatment of hormone receptor-positive, human epidermal growth factor 2-negative, high risk, early breast cancer demonstrated a clinically meaningful improvement in invasive disease-free survival versus ET alone. Detailed safety analyses conducted at a median follow-up of 27 months and key patient-reported outcomes (PRO) are presented. PATIENTS AND METHODS The safety population included all patients who received at least one dose of study treatment (n=5591). Safety analyses included incidence, management, and outcomes of common and clinically relevant adverse events (AEs). Patient-reported health-related quality-of-life, ET symptoms, fatigue, and side effect burden were assessed. RESULTS The addition of abemaciclib to ET resulted in higher incidence of Grade≥3 AEs (49.7% vs 16.3% with ET alone), predominantly laboratory cytopenias (e.g., neutropenia [19.6%]) without clinical complications. Abemaciclib-treated patients experienced more serious adverse events (SAEs; 13.3% vs 7.8%). Discontinuation of abemaciclib and/or ET due to AEs occurred in 18.5% of patients, mainly due to Grade1/2 AEs (66.8%). AEs were managed with comedications (e.g., antidiarrheals), abemaciclib dose holds (61.7%), and/or dose reductions (43.4%). Diarrhea was generally low grade (Grade1/2: 77%); Grade2/3 events were highest in the first month (20.5%), most short-lived (≤7 days) and did not recur. Venous thromboembolic events (VTE) were higher with abemaciclib+ET (2.5%) vs ET (0.6%); in the abemaciclib arm, increased VTE risk was observed with tamoxifen vs AIs (4.3% vs 1.8%). PROs were similar between arms, including being 'bothered by side effects of treatment', except for diarrhea. At ≥3 months, most patients reporting diarrhea reported "a little bit" or "somewhat". CONCLUSION In patients with high risk EBC, adjuvant abemaciclib+ET has an acceptable safety profile and tolerability is supported by PRO findings. Most AEs were reversible and manageable with comedications and/or dose modifications, consistent with the known abemaciclib toxicity profile.
Collapse
Affiliation(s)
- H S Rugo
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, USA.
| | - J O'Shaughnessy
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas TX, USA
| | - F Boyle
- Patricia Ritchie Centre for Cancer Care and Research, Mater Hospital, Sydney; University of Sydney, Sydney, Australia
| | - M Toi
- Kyoto University Hospital, Kyoto, Japan
| | - R Broom
- Auckland City Hospital, Auckland, New Zealand
| | - I Blancas
- Hospital Universitario Clínico San Cecilio, Granada, Spain; Medicine Department. University of Granada, Spain
| | - M Gumus
- Istanbul Medeniyet University, School of Medicine, Istanbul, Turkey
| | | | - Y-H Im
- Division of Hematology/Medical Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - P Rastogi
- University of Pittsburgh/UPMC, NSABP Foundation, Pittsburgh, USA
| | - F Zagouri
- National and Kapodistrian University of Athens, Department of Clinical Therapeutics, School of Medicine, Athens, Greece
| | - C Song
- Fujian Medical University Union Hospital, Fujian, China
| | - M Campone
- Institut de Cancérologie de l'Ouest, Centre René Gauducheau, Nantes / Saint-Herblain, France
| | | | - A Shahir
- Eli Lilly and Company, Indianapolis, USA
| | - M Hulstijn
- Eli Lilly and Company, Indianapolis, USA
| | - J Brown
- Eli Lilly and Company, Indianapolis, USA
| | | | - Ran Wei
- Eli Lilly and Company, Indianapolis, USA
| | - S Johnston
- Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - M Reinisch
- Breast Unit, Kliniken Essen-Mitte, Essen, Germany
| | | | | |
Collapse
|
17
|
Raj S, McCafferty D, Lubrasky G, Johnston S, Skillen KL, McLaughlin J. Point-of-Care Monitoring of Respiratory Diseases Using Lateral Flow Assay and CMOS Camera Reader. IEEE J Transl Eng Health Med 2022; 10:2800208. [PMID: 35992371 PMCID: PMC9384958 DOI: 10.1109/jtehm.2022.3193575] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/16/2022] [Revised: 06/24/2022] [Accepted: 07/14/2022] [Indexed: 11/06/2022]
Affiliation(s)
- Shasidran Raj
- Connected Health Innovation Centre, NIBEC, Ulster University, Belfast, U.K
| | | | - Gennady Lubrasky
- Connected Health Innovation Centre, NIBEC, Ulster University, Belfast, U.K
| | | | - Kerry-Louise Skillen
- Eastern Corridor Medical Engineering Centre, NIBEC, Ulster University, Belfast, U.K
| | - James McLaughlin
- Connected Health Innovation Centre, NIBEC, Ulster University, Belfast, U.K
| |
Collapse
|
18
|
Battisti N, McGinn M, Ashurst I, Snuggs N, Crimmin J, Cowan-Dickie S, Pessoa Silva M, Eldridge L, Tomlins E, Roe J, Lister S, Grayer J, Stanley P, Mann L, Spurgeon H, Droney J, McGrath S, Hill N, Farthing L, Begum S, Waller J, Bateman E, Kipps E, Sinclair S, Johnston S, Ring A. Evaluating the needs of older adults with cancer: baseline clinical activity and considerations for the development of a Senior Adult Oncology Programme at The Royal Marsden. J Geriatr Oncol 2021. [DOI: 10.1016/s1879-4068(21)00424-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
19
|
Battisti N, McGinn M, Ashurst I, Snuggs N, Crimmin J, Cowan-Dickie S, Pessoa Silva M, Eldridge L, Tomlins E, Roe J, Lister S, Grayer J, Stanley P, Mann L, Spurgeon H, Droney J, McGrath S, Hill N, Farthing L, Begum S, Joanna Waller J, Bateman E, Kipps E, Sinclair S, Johnston S, Ring A. Pioneering comprehensive oncogeriatric care in the United Kingdom: the development of a multidisciplinary Senior Adult Oncology Programme at The Royal Marsden. J Geriatr Oncol 2021. [DOI: 10.1016/s1879-4068(21)00423-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
20
|
Ideta S, Johnston S, Yoshida T, Tanaka K, Mori M, Anzai H, Ino A, Arita M, Namatame H, Taniguchi M, Ishida S, Takashima K, Kojima KM, Devereaux TP, Uchida S, Fujimori A. Hybridization of Bogoliubov Quasiparticles between Adjacent CuO_{2} Layers in the Triple-Layer Cuprate Bi_{2}Sr_{2}Ca_{2}Cu_{3}O_{10+δ} Studied by Angle-Resolved Photoemission Spectroscopy. Phys Rev Lett 2021; 127:217004. [PMID: 34860085 DOI: 10.1103/physrevlett.127.217004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/10/2020] [Revised: 07/08/2021] [Accepted: 10/20/2021] [Indexed: 06/13/2023]
Abstract
Hybridization of Bogoliubov quasiparticles (BQPs) between the CuO_{2} layers in the triple-layer cuprate high-temperature superconductor Bi_{2}Sr_{2}Cu_{2}Cu_{3}O_{10+δ} is studied by angle-resolved photoemission spectroscopy (ARPES). In the superconducting state, an anticrossing gap opens between the outer- and inner-BQP bands, which we attribute primarily to interlayer single-particle hopping with possible contributions from interlayer Cooper pairing. We find that the d-wave superconducting gap of both BQP bands smoothly develops with momentum without an abrupt jump in contrast to a previous ARPES study. Hybridization between the BQPs also gradually increases in going from the off nodal to the antinodal region, which is explained by the momentum dependence of the interlayer single-particle hopping. As possible mechanisms for the enhancement of the superconducting transition temperature, the hybridization between the BQPs as well as the combination of phonon modes of the triple CuO_{2} layers and spin fluctuations represented by a four-well model are discussed.
Collapse
Affiliation(s)
- S Ideta
- Department of Physics, University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan
- UVSOR-III Synchrotron, Institute for Molecular Science, Okazaki 444-8585, Japan
| | - S Johnston
- Department of Physics and Astronomy, The University of Tennessee, Knoxville, Tennessee 37996, USA
| | - T Yoshida
- Department of Human and Environmental studies, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan
| | - K Tanaka
- UVSOR-III Synchrotron, Institute for Molecular Science, Okazaki 444-8585, Japan
| | - M Mori
- Advanced Science Research Center, Japan Atomic Energy Agency, Tokai 319-1195, Japan
| | - H Anzai
- Graduate School of Engineering, Osaka Prefecture University, Sakai 599-8531, Japan
- Graduate School of Science, Hiroshima University, Higashi-Hiroshima 739-8526, Japan
| | - A Ino
- Graduate School of Science, Hiroshima University, Higashi-Hiroshima 739-8526, Japan
- Hiroshima Synchrotron Radiation Center, Hiroshima University, Higashi-Hiroshima 739-0046, Japan
- Department of Education and Creation Engineering, Kurume Institute of Technology, Fukuoka 2286-66, Japan
| | - M Arita
- Hiroshima Synchrotron Radiation Center, Hiroshima University, Higashi-Hiroshima 739-0046, Japan
| | - H Namatame
- Hiroshima Synchrotron Radiation Center, Hiroshima University, Higashi-Hiroshima 739-0046, Japan
| | - M Taniguchi
- Graduate School of Science, Hiroshima University, Higashi-Hiroshima 739-8526, Japan
- Hiroshima Synchrotron Radiation Center, Hiroshima University, Higashi-Hiroshima 739-0046, Japan
| | - S Ishida
- Department of Physics, University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan
- National Institute of Advanced Industrial Science and Technology, Tsukuba, Ibaraki 305-8568, Japan
| | - K Takashima
- Department of Physics, University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - K M Kojima
- Department of Physics, University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan
- J-PARC Center and Institute of Materials Structure Science, KEK, Tsukuba, Ibaraki 305-0801, Japan
- Centre for Molecular and Materials Science, TRIUMF, 4004 Vancouver, Canada
| | - T P Devereaux
- Geballe Laboratory for Advanced Materials, Stanford University, Stanford, California 94305, USA
- Stanford Institute for Materials and Energy Sciences, SLAC National Laboratory and Stanford University, Menlo Park, California 94025, USA
- Department of Materials Science and Engineering Stanford University, Stanford, California 94305, USA
| | - S Uchida
- Department of Physics, University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan
- National Institute of Advanced Industrial Science and Technology, Tsukuba, Ibaraki 305-8568, Japan
| | - A Fujimori
- Department of Physics, University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan
- Department of Applied Physics, Waseda University, Shinjuku-ku, Tokyo 169-8555, Japan
| |
Collapse
|
21
|
Harbeck N, Rastogi P, Shahir A, Johnston S, O'Shaughnessy J. Letter to the Editor for 'Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study'. Ann Oncol 2021; 33:227-228. [PMID: 34756989 DOI: 10.1016/j.annonc.2021.10.015] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2021] [Accepted: 10/22/2021] [Indexed: 11/01/2022] Open
Affiliation(s)
- N Harbeck
- Breast Center, LMU University Hospital, Munich, Germany.
| | - P Rastogi
- University of Pittsburgh/UPMC, NSABP Foundation, Pittsburgh, USA
| | - A Shahir
- Eli Lilly and Company, Indianapolis, USA
| | - S Johnston
- Royal Marsden NHS Foundation Trust, London, UK
| | - J O'Shaughnessy
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, USA
| |
Collapse
|
22
|
O'Sullivan RJ, Aykanat T, Johnston S, Rogan G, Poole R, Prodöhl PA, de Eyto E, Primmer CR, McGinnity P, Reed TE. Correction to: 'Captive-bred Atlantic salmon released into the wild have fewer offspring than wild-bred fish and decrease population productivity'. Proc Biol Sci 2021; 288:20211244. [PMID: 34187200 DOI: 10.1098/rspb.2021.1244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
23
|
Gwiti P, Melegh Z, Johnston S, Sutak J. Paraneoplastic pemphigus caused by pre-existing stroma-rich variant of Castleman disease: from a pathologist's point of view. BMJ Case Rep 2021; 14:e241374. [PMID: 33975839 PMCID: PMC8118026 DOI: 10.1136/bcr-2020-241374] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/11/2021] [Indexed: 11/04/2022] Open
Abstract
A young woman presented with mucocutaneous blisters and ulcerating lesions, and was diagnosed with erythrodermic pemphigus complicated by bronchiolitis obliterans. Her clinical condition did not improve on immunosuppressive therapy. She had a history of an asymptomatic retroperitoneal mass, presumed to be a dermoid cyst, followed up clinically. Due to the pre-existing nature of the retroperitoneal mass, the paraneoplastic nature of the pemphigus was initially not recognised, but after a multidisciplinary team meeting a biopsy was performed. Histology revealed a rare stroma-rich variant of Castleman disease with a prominent stroma demonstrating a myoid phenotype. Resection of the retroperitoneal tumour resulted in resolution of the cutaneous blisters. This emphasises the importance to consider paraneoplastic disease in treatment-resistant pemphigus as surgical removal of the tumour forms the mainstay of therapy. The differential diagnosis should include Castleman disease and careful evaluation of histology is essential with the awareness of this rare stroma-rich variant.
Collapse
Affiliation(s)
- Paida Gwiti
- Department of Cellular Pathology, Peterborough City Hospital, Peterborough, Cambridgeshire, UK
| | - Zsombor Melegh
- Centre for Medical Education, University of Bristol, Bristol, UK
- Department of Cellular Pathology, North Bristol NHS Trust, Westbury on Trym, UK
| | - Sarah Johnston
- Department of Immunology, North Bristol NHS Trust, Westbury on Trym, Bristol, UK
| | - Judit Sutak
- Department of Cellular Pathology, North Bristol NHS Trust, Westbury on Trym, UK
| |
Collapse
|
24
|
Grammatikos A, Johnston S, Rice CM, Gompels M. A Family with a Novel CTLA4 Haploinsufficiency Mutation and Neurological Symptoms. J Clin Immunol 2021; 41:1411-1416. [PMID: 33956248 PMCID: PMC8310858 DOI: 10.1007/s10875-021-01027-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2020] [Accepted: 03/17/2021] [Indexed: 10/26/2022]
|
25
|
Dasari TW, Csipo T, Amil F, Lipecz A, Fulop GA, Jiang Y, Samannan R, Johnston S, Zhao YD, Silva-Palacios F, Stavrakis S, Yabluchanskiy A, Po SS. Effects of Low-Level Tragus Stimulation on Endothelial Function in Heart Failure With Reduced Ejection Fraction. J Card Fail 2021; 27:568-576. [PMID: 33387632 PMCID: PMC9473302 DOI: 10.1016/j.cardfail.2020.12.017] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2020] [Revised: 12/14/2020] [Accepted: 12/21/2020] [Indexed: 01/23/2023]
Abstract
BACKGROUND Autonomic dysregulation in heart failure with reduced ejection fraction plays a major role in endothelial dysfunction. Low-level tragus stimulation (LLTS) is a novel, noninvasive method of autonomic modulation. METHODS AND RESULTS We enrolled 50 patients with heart failure with reduced ejection fraction (left ventricular ejection fraction of ≤40%) in a randomized, double-blinded, crossover study. On day 1, patients underwent 60 minutes of LLTS with a transcutaneous stimulator (20 Hz, 200 μs pulse width) or sham (ear lobule) stimulation. Macrovascular function was assessed using flow-mediated dilatation in the brachial artery and cutaneous microcirculation with laser speckle contrast imaging in the hand and nail bed. On day 2, patients were crossed over to the other study arm and underwent sham or LLTS; vascular tests were repeated before and after stimulation. Compared with the sham, LLTS improved flow-mediated dilatation by increasing the percent change in the brachial artery diameter (from 5.0 to 7.5, LLTS on day 1, P = .02; and from 4.9 to 7.1, LLTS on day 2, P = .003), compared with no significant change in the sham group (from 4.6 to 4.7, P = .84 on day 1; and from 5.6 to 5.9 on day 2, P = .65). Cutaneous microcirculation in the hand showed no improvement and perfusion of the nail bed showed a trend toward improvement. CONCLUSIONS Our study demonstrated the beneficial effects of acute neuromodulation on macrovascular function. Larger studies to validate these findings and understand mechanistic links are warranted.
Collapse
Affiliation(s)
- Tarun W Dasari
- Cardiovascular Section, Department of Internal Medicine; Heart Rhythm Institute.
| | - Tamas Csipo
- Department of Biochemistry and Molecular Biology; Section of Geriatrics, Department of Internal Medicine
| | - Faris Amil
- Cardiovascular Section, Department of Internal Medicine
| | - Agnes Lipecz
- Department of Biochemistry and Molecular Biology; Section of Geriatrics, Department of Internal Medicine
| | - Gabor A Fulop
- Department of Biochemistry and Molecular Biology; Section of Geriatrics, Department of Internal Medicine
| | | | | | - Sarah Johnston
- Department of Biostatistics and Epidemiology, College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
| | - Yan D Zhao
- Department of Biostatistics and Epidemiology, College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
| | | | - Stavros Stavrakis
- Cardiovascular Section, Department of Internal Medicine; Heart Rhythm Institute
| | - Andriy Yabluchanskiy
- Department of Biochemistry and Molecular Biology; Section of Geriatrics, Department of Internal Medicine
| | - Sunny S Po
- Cardiovascular Section, Department of Internal Medicine; Heart Rhythm Institute
| |
Collapse
|
26
|
Adhikari D, Albataineh H, Androic D, Aniol K, Armstrong DS, Averett T, Ayerbe Gayoso C, Barcus S, Bellini V, Beminiwattha RS, Benesch JF, Bhatt H, Bhatta Pathak D, Bhetuwal D, Blaikie B, Campagna Q, Camsonne A, Cates GD, Chen Y, Clarke C, Cornejo JC, Covrig Dusa S, Datta P, Deshpande A, Dutta D, Feldman C, Fuchey E, Gal C, Gaskell D, Gautam T, Gericke M, Ghosh C, Halilovic I, Hansen JO, Hauenstein F, Henry W, Horowitz CJ, Jantzi C, Jian S, Johnston S, Jones DC, Karki B, Katugampola S, Keppel C, King PM, King DE, Knauss M, Kumar KS, Kutz T, Lashley-Colthirst N, Leverick G, Liu H, Liyange N, Malace S, Mammei R, Mammei J, McCaughan M, McNulty D, Meekins D, Metts C, Michaels R, Mondal MM, Napolitano J, Narayan A, Nikolaev D, Rashad MNH, Owen V, Palatchi C, Pan J, Pandey B, Park S, Paschke KD, Petrusky M, Pitt ML, Premathilake S, Puckett AJR, Quinn B, Radloff R, Rahman S, Rathnayake A, Reed BT, Reimer PE, Richards R, Riordan S, Roblin Y, Seeds S, Shahinyan A, Souder P, Tang L, Thiel M, Tian Y, Urciuoli GM, Wertz EW, Wojtsekhowski B, Yale B, Ye T, Yoon A, Zec A, Zhang W, Zhang J, Zheng X. Accurate Determination of the Neutron Skin Thickness of ^{208}Pb through Parity-Violation in Electron Scattering. Phys Rev Lett 2021; 126:172502. [PMID: 33988387 DOI: 10.1103/physrevlett.126.172502] [Citation(s) in RCA: 31] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/22/2021] [Accepted: 03/22/2021] [Indexed: 06/12/2023]
Abstract
We report a precision measurement of the parity-violating asymmetry A_{PV} in the elastic scattering of longitudinally polarized electrons from ^{208}Pb. We measure A_{PV}=550±16(stat)±8(syst) parts per billion, leading to an extraction of the neutral weak form factor F_{W}(Q^{2}=0.00616 GeV^{2})=0.368±0.013. Combined with our previous measurement, the extracted neutron skin thickness is R_{n}-R_{p}=0.283±0.071 fm. The result also yields the first significant direct measurement of the interior weak density of ^{208}Pb: ρ_{W}^{0}=-0.0796±0.0036(exp)±0.0013(theo) fm^{-3} leading to the interior baryon density ρ_{b}^{0}=0.1480±0.0036(exp)±0.0013(theo) fm^{-3}. The measurement accurately constrains the density dependence of the symmetry energy of nuclear matter near saturation density, with implications for the size and composition of neutron stars.
Collapse
Affiliation(s)
- D Adhikari
- Idaho State University, Pocatello, ID 83209, USA
| | - H Albataineh
- Texas A & M University-Kingsville, Kingsville, TX 78363, USA
| | - D Androic
- University of Zagreb, Faculty of Science
| | - K Aniol
- California State University, Los Angeles, Los Angeles, California 90032, USA
| | | | - T Averett
- William & Mary, Williamsburg, Virginia 23185, USA
| | | | - S Barcus
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - V Bellini
- Istituto Nazionale di Fisica Nucleare, Sezione di Catania, 95123 Catania, Italy
| | | | - J F Benesch
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - H Bhatt
- Mississippi State University, Mississippi State, MS 39762, USA
| | | | - D Bhetuwal
- Mississippi State University, Mississippi State, MS 39762, USA
| | - B Blaikie
- University of Manitoba, Winnipeg, MB R3T2N2 Canada
| | - Q Campagna
- William & Mary, Williamsburg, Virginia 23185, USA
| | - A Camsonne
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - G D Cates
- University of Virginia, Charlottesville, VA 22904, USA
| | - Y Chen
- Louisiana Tech University, Ruston, LA 71272 USA
| | - C Clarke
- Stony Brook, State University of New York, NY 11794, USA
| | - J C Cornejo
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - S Covrig Dusa
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - P Datta
- University of Connecticut, Storrs, CT 06269, USA
| | - A Deshpande
- Stony Brook, State University of New York, NY 11794, USA
- Center for Frontiers in Nuclear Science, NY 11794, USA
| | - D Dutta
- Mississippi State University, Mississippi State, MS 39762, USA
| | - C Feldman
- Stony Brook, State University of New York, NY 11794, USA
| | - E Fuchey
- University of Connecticut, Storrs, CT 06269, USA
| | - C Gal
- University of Virginia, Charlottesville, VA 22904, USA
- Stony Brook, State University of New York, NY 11794, USA
- Center for Frontiers in Nuclear Science, NY 11794, USA
| | - D Gaskell
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - T Gautam
- Hampton University, Hampton, Virginia 23668, USA
| | - M Gericke
- University of Manitoba, Winnipeg, MB R3T2N2 Canada
| | - C Ghosh
- Stony Brook, State University of New York, NY 11794, USA
- University of Massachusetts Amherst, Amherst, Massachusetts 01003, USA
| | - I Halilovic
- University of Manitoba, Winnipeg, MB R3T2N2 Canada
| | - J-O Hansen
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - F Hauenstein
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - W Henry
- Temple University, Philadelphia, PA 19122, USA
| | - C J Horowitz
- Indiana University, Bloomington, Indiana 47405, USA
| | - C Jantzi
- University of Virginia, Charlottesville, VA 22904, USA
| | - S Jian
- University of Virginia, Charlottesville, VA 22904, USA
| | - S Johnston
- University of Massachusetts Amherst, Amherst, Massachusetts 01003, USA
| | - D C Jones
- Temple University, Philadelphia, PA 19122, USA
| | - B Karki
- Ohio University, Athens, Ohio 45701, USA
| | - S Katugampola
- University of Virginia, Charlottesville, VA 22904, USA
| | - C Keppel
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - P M King
- Ohio University, Athens, Ohio 45701, USA
| | - D E King
- Syracuse University, Syracuse, New York 13244, USA
| | - M Knauss
- Duquesne University, 600 Forbes Avenue, Pittsburgh, PA 15282, USA
| | - K S Kumar
- University of Massachusetts Amherst, Amherst, Massachusetts 01003, USA
| | - T Kutz
- Stony Brook, State University of New York, NY 11794, USA
| | | | - G Leverick
- University of Manitoba, Winnipeg, MB R3T2N2 Canada
| | - H Liu
- University of Massachusetts Amherst, Amherst, Massachusetts 01003, USA
| | - N Liyange
- University of Virginia, Charlottesville, VA 22904, USA
| | - S Malace
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - R Mammei
- University of Winnipeg, Winnipeg, MB R3B2E9 Canada
| | - J Mammei
- University of Manitoba, Winnipeg, MB R3T2N2 Canada
| | - M McCaughan
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - D McNulty
- Idaho State University, Pocatello, ID 83209, USA
| | - D Meekins
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - C Metts
- William & Mary, Williamsburg, Virginia 23185, USA
| | - R Michaels
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M M Mondal
- Stony Brook, State University of New York, NY 11794, USA
- Center for Frontiers in Nuclear Science, NY 11794, USA
| | | | | | - D Nikolaev
- Temple University, Philadelphia, PA 19122, USA
| | - M N H Rashad
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - V Owen
- William & Mary, Williamsburg, Virginia 23185, USA
| | - C Palatchi
- University of Virginia, Charlottesville, VA 22904, USA
- Center for Frontiers in Nuclear Science, NY 11794, USA
| | - J Pan
- University of Manitoba, Winnipeg, MB R3T2N2 Canada
| | - B Pandey
- Hampton University, Hampton, Virginia 23668, USA
| | - S Park
- Stony Brook, State University of New York, NY 11794, USA
| | - K D Paschke
- University of Virginia, Charlottesville, VA 22904, USA
| | - M Petrusky
- Stony Brook, State University of New York, NY 11794, USA
| | - M L Pitt
- Virginia Tech, Blacksburg, Virginia 24061, USA
| | | | | | - B Quinn
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - R Radloff
- Ohio University, Athens, Ohio 45701, USA
| | - S Rahman
- University of Manitoba, Winnipeg, MB R3T2N2 Canada
| | - A Rathnayake
- University of Virginia, Charlottesville, VA 22904, USA
| | - B T Reed
- Indiana University, Bloomington, Indiana 47405, USA
| | - P E Reimer
- Physics Division, Argonne National Laboratory, Lemont, Il 60439
| | - R Richards
- Stony Brook, State University of New York, NY 11794, USA
| | - S Riordan
- Physics Division, Argonne National Laboratory, Lemont, Il 60439
| | - Y Roblin
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S Seeds
- University of Connecticut, Storrs, CT 06269, USA
| | - A Shahinyan
- A. I. Alikhanyan National Science Laboratory (Yerevan Physics Institute), Yerevan 0036, Armenia
| | - P Souder
- Syracuse University, Syracuse, New York 13244, USA
| | - L Tang
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
- Hampton University, Hampton, Virginia 23668, USA
| | - M Thiel
- Institut für Kernphysik, Johannes Gutenberg-Universität, Mainz 55122, Germany
| | - Y Tian
- Syracuse University, Syracuse, New York 13244, USA
| | | | - E W Wertz
- William & Mary, Williamsburg, Virginia 23185, USA
| | - B Wojtsekhowski
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - B Yale
- William & Mary, Williamsburg, Virginia 23185, USA
| | - T Ye
- Stony Brook, State University of New York, NY 11794, USA
| | - A Yoon
- Christopher Newport University, Newport News, Virginia 23606, USA
| | - A Zec
- University of Virginia, Charlottesville, VA 22904, USA
| | - W Zhang
- Stony Brook, State University of New York, NY 11794, USA
| | - J Zhang
- Stony Brook, State University of New York, NY 11794, USA
- Center for Frontiers in Nuclear Science, NY 11794, USA
- Shandong University, Qingdao, Shandong 266237, China
| | - X Zheng
- University of Virginia, Charlottesville, VA 22904, USA
| |
Collapse
|
27
|
Morawska A, Baker S, Johnston S. “The parent trap”: gender stereotypes and parenting roles in an Australian parenting website. Australian Journal of Psychology 2021. [DOI: 10.1080/00049530.2021.1906162] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- Alina Morawska
- Parenting and Family Support Centre, School of Psychology, The University of Queensland, St. Lucia, Australia
| | - Sabine Baker
- Parenting and Family Support Centre, School of Psychology, The University of Queensland, St. Lucia, Australia
| | - Sarah Johnston
- Parenting and Family Support Centre, School of Psychology, The University of Queensland, St. Lucia, Australia
| |
Collapse
|
28
|
Abstract
AbstractWe report on the management of three cases of rectal stump leak and sepsis following urgent Hartmann’s procedure for perforated sigmoid diverticulitis or large bowel obstruction. Two patients had significant risk factors for poor tissue healing. All patients developed features of sepsis and computer tomography scans demonstrated rectal stump leak with adjacent collections. All patients required reoperation for drainage and washout of abscess. An intraperitoneal catheter system was introduced together with drains in order to continue on the ward until tract was formed. There was no mortality and minimal morbidity. The key to management of rectal stump leak is the early and aggressive drainage of the associated collection and continued irrigation of the stump.
Collapse
Affiliation(s)
- Sarah Johnston
- Nepean and Blue Mountains Local Health District, Department of Colorectal Surgery, Sydney, Australia
| | - Penelope De Lacavalerie
- Nepean and Blue Mountains Local Health District, Department of Colorectal Surgery, Sydney, Australia
- University of New South Wales-Sydney, Conjoint Associate Lecturer South West Clinical School, Liverpool, Australia
| |
Collapse
|
29
|
Parker CN, Harvey T, Johnston S, MacAndrew M. An exploration of knowledge of students and staff at residential aged care facilities and implications for nursing education. Nurse Educ Today 2021; 96:104639. [PMID: 33142221 DOI: 10.1016/j.nedt.2020.104639] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/20/2020] [Revised: 07/22/2020] [Accepted: 10/13/2020] [Indexed: 06/11/2023]
Abstract
BACKGROUND Advances in healthcare have contributed to population longevity with many older adults living with complex comorbidities, including those in residential aged care facilities (RACFs). Nursing staff require knowledge of gerontology, normal ageing processes and expected physiological, psychosocial, function and cognitive changes in addition to health promotion in order to provide individualised care. The complexity inherent in the medical, palliative and basic care needs of the residents makes RACFs excellent places for learning for undergraduate student nurses who undertake clinical placement as part of a Bachelor of Nursing course. Previous research has identified that knowledge of care staff is relatively poor. OBJECTIVES To explore the knowledge and misconceptions of ageing among first year undergraduate nursing students and aged care staff facilitating a placement during a clinical learning experience. DESIGN Descriptive cross-sectional design. SETTING Three clinical RACFs in Australia. PARTICIPANTS First year nursing students and staff of three different RACFs. METHOD Pre and post-test clinical placement surveys. Students and staff completed Palmore's Facts on Ageing Quiz, a 25-item tool to assess knowledge and attitudes of ageing, before commencing the clinical placement and on the last day of a two week placement. RESULTS Physiological questions were answered correctly. A knowledge deficit was evident from a sociological perspective. Negative attitudes have been found to devalue care and can directly affect the quality of practice in an undesirable way, forming a barrier to effective and therapeutic relationships with older adults, potentially impacting on patient care. CONCLUSIONS From an education provider perspective, the inclusion of activities to enrich the learning activities of nurses within RACF- inclusive of reflective activities and guidance from an expert clinical facilitator - may assist in dispelling negative attitudes and stereotypes of the older adult and increase recognition of the value of working with older adults.
Collapse
Affiliation(s)
- C N Parker
- Faculty of Health, Queensland University of Technology, Victoria Park Rd, Kelvin Grove, QLD 4059, Australia; Institute of Health & Biomedical Innovation, Queensland University of Technology, 60 Musk Ave. Kelvin Grove, QLD 4059, Australia.
| | - T Harvey
- Faculty of Health Sciences, Australian Catholic University, 1100 Nudgee Rd, Banyo, QLD 4014, Australia
| | - S Johnston
- Faculty of Health, Queensland University of Technology, Victoria Park Rd, Kelvin Grove, QLD 4059, Australia; Institute of Health & Biomedical Innovation, Queensland University of Technology, 60 Musk Ave. Kelvin Grove, QLD 4059, Australia
| | - M MacAndrew
- Faculty of Health, Queensland University of Technology, Victoria Park Rd, Kelvin Grove, QLD 4059, Australia; Institute of Health & Biomedical Innovation, Queensland University of Technology, 60 Musk Ave. Kelvin Grove, QLD 4059, Australia
| |
Collapse
|
30
|
Crespo F, Wilson R, Díaz-Jimenez M, Consuegra C, Dorado J, Barrado BG, Gosálvez J, Smit RL, Hidalgo M, Johnston S. Effect of season on individual stallion semen characteristics. Anim Reprod Sci 2020; 223:106641. [PMID: 33160762 DOI: 10.1016/j.anireprosci.2020.106641] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2020] [Revised: 10/20/2020] [Accepted: 10/21/2020] [Indexed: 11/28/2022]
Abstract
Horses are long-day seasonal breeding animals, however, with modern stallion reproductive management it is important for collection of semen during periods that are not part of the traditional breeding season. This study was conducted to examine variation in the seminal characteristics of individual stallions in Avila, Spain during 1 year with a particular emphasis on sperm DNA fragmentation. Semen was collected twice per season from a total of 20 stallions. There was a marked seasonal effect on all seminal characteristics, with the greatest on progressive motility, % membrane integrity and least for SDF in the spring months; there was also an interaction effect with respect to individual stallion, indicating that some stallions did not fit this generalised pattern for semen quality. Sperm DNA fragmentation was assessed both immediately after semen collection (T0) and following incubation of extended semen for 24 h (T24) to broadly mimic changes in SDF that might occur in the female reproductive tract. While SDF evaluated at T0 was also generally less in spring, the proportion of stallions with the least SDF values in spring increased from 45% to 60% when assessed at T24, therefore, being consistent with the importance of dynamic SDF assessment in detecting DNA damage that was not detected at T0 or cryptic DNA damage. The results from this study indicate there is individual seasonal variation among stallions in all aspects of seminal characteristics; such variation needs to be considered when prioritising stallions that are to be used for breeding.
Collapse
Affiliation(s)
- F Crespo
- Centro Militar de Cría Caballar de Ávila, Cría Caballar de las Fuerzas Armadas, Ávila, 05005, Spain
| | - R Wilson
- School of Mathematics and Physics, The University of Queensland, St Lucia, 4072, Australia
| | - M Díaz-Jimenez
- Veterinary Reproduction Group, Department of Animal Medicine and Surgery, University of Cordoba, Cordoba, 14071, Spain
| | - C Consuegra
- Veterinary Reproduction Group, Department of Animal Medicine and Surgery, University of Cordoba, Cordoba, 14071, Spain
| | - J Dorado
- Veterinary Reproduction Group, Department of Animal Medicine and Surgery, University of Cordoba, Cordoba, 14071, Spain
| | - B García Barrado
- Veterinary Reproduction Group, Department of Animal Medicine and Surgery, University of Cordoba, Cordoba, 14071, Spain
| | - J Gosálvez
- Department of Biology, Genetics Unit, Universidad Autónoma de Madrid (UAM) 20849. Madrid, Spain
| | - R Louis Smit
- School of Agriculture and Food Sciences, The University of Queensland, Gatton, 4343, Australia
| | - M Hidalgo
- Veterinary Reproduction Group, Department of Animal Medicine and Surgery, University of Cordoba, Cordoba, 14071, Spain
| | - S Johnston
- School of Agriculture and Food Sciences, The University of Queensland, Gatton, 4343, Australia.
| |
Collapse
|
31
|
Johnston S, Harbeck N, Hegg R, Toi M, Martin M, Shao Z, Campone M, Hamilton E, Sohn J, Guarneri V, Cortes J, Neven P, Boyle F, Smith I, Frenzel M, Headley D, Wei R, Cox J, O'Shaughnessy J, Rastogi P. 2MO Abemaciclib in high risk early breast cancer. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.023] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
32
|
Seligmann JF, Wright-Hughes A, Pottinger A, Velikova G, Oughton JB, Murden G, Rizwanullah M, Price C, Passant H, Heudtlass P, Marshall H, Johnston S, Dodwell D. Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer with Central Nervous System Metastases for Patients Currently or Previously Treated with Trastuzumab (LANTERN): a Phase II Randomised Trial. Clin Oncol (R Coll Radiol) 2020; 32:656-664. [PMID: 32600919 DOI: 10.1016/j.clon.2020.06.003] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2020] [Revised: 05/14/2020] [Accepted: 06/03/2020] [Indexed: 11/12/2022]
Abstract
AIMS Brain (central nervous system; CNS) metastases occur in 30-50% of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). A substantive evidence base for treatment is lacking, but activity with lapatinib plus capecitabine (lap-cap) has been reported. We compared lap-cap with trastuzumab plus capecitabine (tras-cap) in patients with HER2-positive MBC with CNS metastases previously treated with trastuzumab. MATERIALS AND METHODS This open-label randomised phase II screening trial aimed to randomise 130 participants over 2 years to receive lap-cap or tras-cap. Eligible patients had HER2-positive MBC with newly diagnosed or recently progressed CNS metastases; previous, or current, treatment included: trastuzumab, a taxane or anthracycline and recent completion of local cranial therapy. The primary end point was time to progression of CNS metastases within the 24-week trial period. Secondary objectives included CNS response rate, progression-free survival, steroid use for CNS symptoms and feasibility of recruitment to a large phase III trial. RESULTS Between September 2011 and October 2013, 30 participants were randomised, 16 to lap-cap and 14 to tras-cap. Recruitment to a large phase III trial was determined not to be feasible. At 24 weeks, CNS disease progression was 41.8% (95% confidence interval 16.1-67.5%) in lap-cap and 41.2% (95% confidence interval 12.8-69.6%) in tras-cap arms; progression-free survival was 44.4% (95% confidence interval 18.1-70.8%) in lap-cap and 50.0% (95% confidence interval 20.9-79.1%) in tras-cap arms. CONCLUSION Poor recruitment confirmed that a larger phase III trial would not be feasible and prohibited a preliminary evaluation of the superiority of lap-cap over tras-cap. Descriptive statistics are presented to inform the limited evidence base and future study design.
Collapse
Affiliation(s)
- J F Seligmann
- Clinical Trials Research Unit, University of Leeds, Leeds, UK
| | - A Wright-Hughes
- Clinical Trials Research Unit, University of Leeds, Leeds, UK
| | - A Pottinger
- Clinical Trials Research Unit, University of Leeds, Leeds, UK
| | - G Velikova
- St James's Institute of Oncology, St James University Hospital, Leeds, UK
| | - J B Oughton
- Clinical Trials Research Unit, University of Leeds, Leeds, UK
| | - G Murden
- Clinical Trials Research Unit, University of Leeds, Leeds, UK
| | - M Rizwanullah
- Department of Clinical Oncology, The Beatson West of Scotland Cancer Centre, Glasgow, UK
| | - C Price
- Department of Medical Oncology, University Hospitals, Bristol, UK
| | - H Passant
- Department of Medical Oncology, Velindre Hospital, Cardiff, UK
| | - P Heudtlass
- Clinical Trials Research Unit, University of Leeds, Leeds, UK
| | - H Marshall
- Clinical Trials Research Unit, University of Leeds, Leeds, UK
| | - S Johnston
- Department of Medical Oncology, The Royal Marsden NHS Foundation Trust, London, UK
| | - D Dodwell
- St James's Institute of Oncology, St James University Hospital, Leeds, UK; Nuffield Department of Population Health, Oxford University, Oxford, UK.
| |
Collapse
|
33
|
Grammatikos A, Albur M, Gompels M, Barnaby CL, Allan S, Johnston S. Antibiotic prophylaxis for the prevention of respiratory tract infections in antibody deficient patients: A retrospective cohort study. Clinical Infection in Practice 2020. [DOI: 10.1016/j.clinpr.2020.100048] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
34
|
Lim ST, Kelly M, Johnston S. Re: 'Readability of online patient education material for the novel coronavirus disease (COVID-19): a cross-sectional health literacy study'. Public Health 2020; 190:145-146. [PMID: 33097240 PMCID: PMC7834890 DOI: 10.1016/j.puhe.2020.09.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2020] [Accepted: 09/01/2020] [Indexed: 11/17/2022]
Affiliation(s)
- S-T Lim
- Department of Surgery, University Hospital Limerick, St Nessan's Rd, Dooradoyle, Co. Limerick, V94 F858, Ireland; Midland Regional Hospital Tullamore, Arden Rd, Puttaghan, Tullamore, Co, Offaly, R35, NY51, Ireland.
| | - M Kelly
- Department of Surgery, University Hospital Limerick, St Nessan's Rd, Dooradoyle, Co, Limerick, V94 F858, Ireland
| | - S Johnston
- Midland Regional Hospital Tullamore, Arden Rd, Puttaghan, Tullamore, Co, Offaly, R35, NY51, Ireland
| |
Collapse
|
35
|
Alsabbagh MW, Kueper JK, Wong ST, Burge F, Johnston S, Peterson S, Lawson B, Chung H, Bennett M, Blackman S, McGrail K, Campbell J, Hogg W, Glazier R. Development of comparable algorithms to measure primary care indicators using administrative health data across three Canadian provinces. Int J Popul Data Sci 2020; 5:1340. [PMID: 33644408 PMCID: PMC7893851 DOI: 10.23889/ijpds.v5i1.1340] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022] Open
Abstract
INTRODUCTION Performance measurement has been recognized as key to transforming primary care (PC). Yet, performance reporting in PC lags behind even though high-performing PC is foundational to an effective and efficient health care system. OBJECTIVES We used administrative data from three Canadian provinces, British Columbia, Ontario and Nova Scotia, to: 1) identify and develop a core set of PC performance indicators using administrative data and 2) examine their ability to capture PC performance. METHODS Administrative data used included Physician Billings, Discharge Abstract Database, the National Ambulatory Care and Reporting System database, Census and Vital Statistics. Indicators were compiled based on a literature review of PC indicators previously developed with administrative data available in Canada (n=158). We engaged in iterative discussions to assess data conformity, completeness, and plausibility of results in all jurisdictions. Challenges to creating comparable algorithms were examined through content analysis and research team discussions, which included clinicians, analysts, and health services researchers familiar with PC. RESULTS Our final list included 21 PC performance indicators pertaining to 1) technical care (n=4), 2) continuity of care (n=6), and 3) health services utilization (n=11). Establishing comparable algorithms across provinces was possible though time intensive. A major challenge was inconsistent data elements. Ease of data access, and a deep understanding of the data and practice context, was essential for selecting the most appropriate data elements. CONCLUSIONS This project is unique in creating algorithms to measure PC performance across provinces. It was essential to balance internal validity of the indicators within a province and external validity across provinces. The intuitive desire of having the exact same coding across provinces was infeasible due to lack of standardized PC data. Rather, a context-tailored definition was developed for each jurisdiction. This work serves as an example for developing comparable PC performance indicators across different provincial/territorial jurisdictions.
Collapse
Affiliation(s)
| | | | - ST Wong
- University of British Columbia
| | | | - S Johnston
- Bruyère Research Institute, University of Ottawa
| | | | | | | | | | | | | | | | - W Hogg
- University of Ottawa, Montfort Hospital Research Institute
| | | |
Collapse
|
36
|
McLean KA, Ahmed WUR, Akhbari M, Claireaux HA, English C, Frost J, Henshall DE, Khan M, Kwek I, Nicola M, Rehman S, Varghese S, Drake TM, Bell S, Nepogodiev D, McLean KA, Drake TM, Glasbey JC, Borakati A, Drake TM, Kamarajah S, McLean KA, Bath MF, Claireaux HA, Gundogan B, Mohan M, Deekonda P, Kong C, Joyce H, Mcnamee L, Woin E, Burke J, Khatri C, Fitzgerald JE, Harrison EM, Bhangu A, Nepogodiev D, Arulkumaran N, Bell S, Duthie F, Hughes J, Pinkney TD, Prowle J, Richards T, Thomas M, Dynes K, Patel M, Patel P, Wigley C, Suresh R, Shaw A, Klimach S, Jull P, Evans D, Preece R, Ibrahim I, Manikavasagar V, Smith R, Brown FS, Deekonda P, Teo R, Sim DPY, Borakati A, Logan AE, Barai I, Amin H, Suresh S, Sethi R, Bolton W, Corbridge O, Horne L, Attalla M, Morley R, Robinson C, Hoskins T, McAllister R, Lee S, Dennis Y, Nixon G, Heywood E, Wilson H, Ng L, Samaraweera S, Mills A, Doherty C, Woin E, Belchos J, Phan V, Chouari T, Gardner T, Goergen N, Hayes JDB, MacLeod CS, McCormack R, McKinley A, McKinstry S, Milligan W, Ooi L, Rafiq NM, Sammut T, Sinclair E, Smith M, Baker C, Boulton APR, Collins J, Copley HC, Fearnhead N, Fox H, Mah T, McKenna J, Naruka V, Nigam N, Nourallah B, Perera S, Qureshi A, Saggar S, Sun L, Wang X, Yang DD, Caroll P, Doyle C, Elangovan S, Falamarzi A, Perai KG, Greenan E, Jain D, Lang-Orsini M, Lim S, O'Byrne L, Ridgway P, Van der Laan S, Wong J, Arthur J, Barclay J, Bradley P, Edwin C, Finch E, Hayashi E, Hopkins M, Kelly D, Kelly M, McCartan N, Ormrod A, Pakenham A, Hayward J, Hitchen C, Kishore A, Martins T, Philomen J, Rao R, Rickards C, Burns N, Copeland M, Durand C, Dyal A, Ghaffar A, Gidwani A, Grant M, Gribbon C, Gruhn A, Leer M, Ahmad K, Beattie G, Beatty M, Campbell G, Donaldson G, Graham S, Holmes D, Kanabar S, Liu H, McCann C, Stewart R, Vara S, Ajibola-Taylor O, Andah EJE, Ani C, Cabdi NMO, Ito G, Jones M, Komoriyama A, Patel P, Titu L, Basra M, Gallogly P, Harinath G, Leong SH, Pradhan A, Siddiqui I, Zaat S, Ali A, Galea M, Looi WL, Ng JCK, Atkin G, Azizi A, Cargill Z, China Z, Elliot J, Jebakumar R, Lam J, Mudalige G, Onyerindu C, Renju M, Babu VS, Hussain M, Joji N, Lovett B, Mownah H, Ali B, Cresswell B, Dhillon AK, Dupaguntla YS, Hungwe C, Lowe-Zinola JD, Tsang JCH, Bevan K, Cardus C, Duggal A, Hossain S, McHugh M, Scott M, Chan F, Evans R, Gurung E, Haughey B, Jacob-Ramsdale B, Kerr M, Lee J, McCann E, O'Boyle K, Reid N, Hayat F, Hodgson S, Johnston R, Jones W, Khan M, Linn T, Long S, Seetharam P, Shaman S, Smart B, Anilkumar A, Davies J, Griffith J, Hughes B, Islam Y, Kidanu D, Mushaini N, Qamar I, Robinson H, Schramm M, Tan CY, Apperley H, Billyard C, Blazeby JM, Cannon SP, Carse S, Göpfert A, Loizidou A, Parkin J, Sanders E, Sharma S, Slade G, Telfer R, Huppatz IW, Worley E, Chandramoorthy L, Friend C, Harris L, Jain P, Karim MJ, Killington K, McGillicuddy J, Rafferty C, Rahunathan N, Rayne T, Varathan Y, Verma N, Zanichelli D, Arneill M, Brown F, Campbell B, Crozier L, Henry J, McCusker C, Prabakaran P, Wilson R, Asif U, Connor M, Dindyal S, Math N, Pagarkar A, Saleem H, Seth I, Sharma S, Standfield N, Swartbol T, Adamson R, Choi JE, El Tokhy O, Ho W, Javaid NR, Kelly M, Mehdi AS, Menon D, Plumptre I, Sturrock S, Turner J, Warren O, Crane E, Ferris B, Gadsby C, Smallwood J, Vipond M, Wilson V, Amarnath T, Doshi A, Gregory C, Kandiah K, Powell B, Spoor H, Toh C, Vizor R, Common M, Dunleavy K, Harris S, Luo C, Mesbah Z, Kumar AP, Redmond A, Skulsky S, Walsh T, Daly D, Deery L, Epanomeritakis E, Harty M, Kane D, Khan K, Mackey R, McConville J, McGinnity K, Nixon G, Ang A, Kee JY, Leung E, Norman S, Palaniappan SV, Sarathy PP, Yeoh T, Frost J, Hazeldine P, Jones L, Karbowiak M, Macdonald C, Mutarambirwa A, Omotade A, Runkel M, Ryan G, Sawers N, Searle C, Suresh S, Vig S, Ahmad A, McGartland R, Sim R, Song A, Wayman J, Brown R, Chang LH, Concannon K, Crilly C, Arnold TJ, Burgin A, Cadden F, Choy CH, Coleman M, Lim D, Luk J, Mahankali-Rao P, Prudence-Taylor AJ, Ramakrishnan D, Russell J, Fawole A, Gohil J, Green B, Hussain A, McMenamin L, McMenamin L, Tang M, Azmi F, Benchetrit S, Cope T, Haque A, Harlinska A, Holdsworth R, Ivo T, Martin J, Nisar T, Patel A, Sasapu K, Trevett J, Vernet G, Aamir A, Bird C, Durham-Hall A, Gibson W, Hartley J, May N, Maynard V, Johnson S, Wood CM, O'Brien M, Orbell J, Stringfellow TD, Tenters F, Tresidder S, Cheung W, Grant A, Tod N, Bews-Hair M, Lim ZH, Lim SW, Vella-Baldacchino M, Auckburally S, Chopada A, Easdon S, Goodson R, McCurdie F, Narouz M, Radford A, Rea E, Taylor O, Yu T, Alfa-Wali M, Amani L, Auluck I, Bruce P, Emberton J, Kumar R, Lagzouli N, Mehta A, Murtaza A, Raja M, Dennahy IS, Frew K, Given A, He YY, Karim MA, MacDonald E, McDonald E, McVinnie D, Ng SK, Pettit A, Sim DPY, Berthaume-Hawkins SD, Charnley R, Fenton K, Jones D, Murphy C, Ng JQ, Reehal R, Robinson H, Seraj SS, Shang E, Tonks A, White P, Yeo A, Chong P, Gabriel R, Patel N, Richardson E, Symons L, Aubrey-Jones D, Dawood S, Dobrzynska M, Faulkner S, Griffiths H, Mahmood F, Patel P, Perry M, Power A, Simpson R, Ali A, Brobbey P, Burrows A, Elder P, Ganyani R, Horseman C, Hurst P, Mann H, Marimuthu K, McBride S, Pilsworth E, Powers N, Stanier P, Innes R, Kersey T, Kopczynska M, Langasco N, Patel N, Rajagopal R, Atkins B, Beasley W, Lim ZC, Gill A, Ang HL, Williams H, Yogeswara T, Carter R, Fam M, Fong J, Latter J, Long M, Mackinnon S, McKenzie C, Osmanska J, Raghuvir V, Shafi A, Tsang K, Walker L, Bountra K, Coldicutt O, Fletcher D, Hudson S, Iqbal S, Bernal TL, Martin JWB, Moss-Lawton F, Smallwood J, Vipond M, Cardwell A, Edgerton K, Laws J, Rai A, Robinson K, Waite K, Ward J, Youssef H, Knight C, Koo PY, Lazarou A, Stanger S, Thorn C, Triniman MC, Botha A, Boyles L, Cumming S, Deepak S, Ezzat A, Fowler AJ, Gwozdz AM, Hussain SF, Khan S, Li H, Morrell BL, Neville J, Nitiahpapand R, Pickering O, Sagoo H, Sharma E, Welsh K, Denley S, Khan S, Agarwal M, Al-Saadi N, Bhambra R, Gupta A, Jawad ZAR, Jiao LR, Khan K, Mahir G, Singagireson S, Thoms BL, Tseu B, Wei R, Yang N, Britton N, Leinhardt D, Mahfooz M, Palkhi A, Price M, Sheikh S, Barker M, Bowley D, Cant M, Datta U, Farooqi M, Lee A, Morley G, Amin MN, Parry A, Patel S, Strang S, Yoganayagam N, Adlan A, Chandramoorthy S, Choudhary Y, Das K, Feldman M, France B, Grace R, Puddy H, Soor P, Ali M, Dhillon P, Faraj A, Gerard L, Glover M, Imran H, Kim S, Patrick Y, Peto J, Prabhudesai A, Smith R, Tang A, Vadgama N, Dhaliwal R, Ecclestone T, Harris A, Ong D, Patel D, Philp C, Stewart E, Wang L, Wong E, Xu Y, Ashaye T, Fozard T, Galloway F, Kaptanis S, Mistry P, Nguyen T, Olagbaiye F, Osman M, Philip Z, Rembacken R, Tayeh S, Theodoropoulou K, Herman A, Lau J, Saha A, Trotter M, Adeleye O, Cave D, Gunwa T, Magalhães J, Makwana S, Mason R, Parish M, Regan H, Renwick P, Roberts G, Salekin D, Sivakumar C, Tariq A, Liew I, McDade A, Stewart D, Hague M, Hudson-Peacock N, Jackson CES, James F, Pitt J, Walker EY, Aftab R, Ang JJ, Anwar S, Battle J, Budd E, Chui J, Crook H, Davies P, Easby S, Hackney E, Ho B, Imam SZ, Rammell J, Andrews H, Perry C, Schinle P, Ahmed P, Aquilina T, Balai E, Church M, Cumber E, Curtis A, Davies G, Dennis Y, Dumann E, Greenhalgh S, Kim P, King S, Metcalfe KHM, Passby L, Redgrave N, Soonawalla Z, Waters S, Zornoza A, Gulzar I, Hole J, Hull K, Ishaq H, Karaj J, Kelkar A, Love E, Patel S, Thakrar D, Vine M, Waterman A, Dib NP, Francis N, Hanson M, Ingleton R, Sadanand KS, Sukirthan N, Arnell S, Ball M, Bassam N, Beghal G, Chang A, Dawe V, George A, Huq T, Hussain A, Ikram B, Kanapeckaite L, Khan M, Ramjas D, Rushd A, Sait S, Serry M, Yardimci E, Capella S, Chenciner L, Episkopos C, Karam E, McCarthy C, Moore-Kelly W, Watson N, Ahluwalia V, Barnfield J, Ben-Gal O, Bloom I, Gharatya A, Khodatars K, Merchant N, Moonan A, Moore M, Patel K, Spiers H, Sundaram K, Turner J, Bath MF, Black J, Chadwick H, Huisman L, Ingram H, Khan S, Martin L, Metcalfe M, Sangal P, Seehra J, Thatcher A, Venturini S, Whitcroft I, Afzal Z, Brown S, Gani A, Gomaa A, Hussein N, Oh SY, Pazhaniappan N, Sharkey E, Sivagnanasithiyar T, Williams C, Yeung J, Cruddas L, Gurjar S, Pau A, Prakash R, Randhawa R, Chen L, Eiben I, Naylor M, Osei-Bordom D, Trenear R, Bannard-Smith J, Griffiths N, Patel BY, Saeed F, Abdikadir H, Bennett M, Church R, Clements SE, Court J, Delvi A, Hubert J, Macdonald B, Mansour F, Patel RR, Perris R, Small S, Betts A, Brown N, Chong A, Croitoru C, Grey A, Hickland P, Ho C, Hollington D, McKie L, Nelson AR, Stewart H, Eiben P, Nedham M, Ali I, Brown T, Cumming S, Hunt C, Joyner C, McAlinden C, Roberts J, Rogers D, Thachettu A, Tyson N, Vaughan R, Verma N, Yasin T, Andrew K, Bhamra N, Leong S, Mistry R, Noble H, Rashed F, Walker NR, Watson L, Worsfold M, Yarham E, Abdikadir H, Arshad A, Barmayehvar B, Cato L, Chan-lam N, Do V, Leong A, Sheikh Z, Zheleniakova T, Coppel J, Hussain ST, Mahmood R, Nourzaie R, Prowle J, Sheik-Ali S, Thomas A, Alagappan A, Ashour R, Bains H, Diamond J, Gordon J, Ibrahim B, Khalil M, Mittapalli D, Neo YN, Patil P, Peck FS, Reza N, Swan I, Whyte M, Chaudhry S, Hernon J, Khawar H, O'Brien J, Pullinger M, Rothnie K, Ujjal S, Bhatte S, Curtis J, Green S, Mayer A, Watkinson G, Chapple K, Hawthorne T, Khaliq M, Majkowski L, Malik TAM, Mclauchlan K, En BNW, Parton S, Robinson SD, Saat MI, Shurovi BN, Varatharasasingam K, Ward AE, Behranwala K, Bertelli M, Cohen J, Duff F, Fafemi O, Gupta R, Manimaran M, Mayhew J, Peprah D, Wong MHY, Farmer N, Houghton C, Kandhari N, Khan K, Ladha D, Mayes J, McLennan F, Panahi P, Seehra H, Agrawal R, Ahmed I, Ali S, Birkinshaw F, Choudhry M, Gokani S, Harrogate S, Jamal S, Nawrozzadeh F, Swaray A, Szczap A, Warusavitarne J, Abdalla M, Asemota N, Cullum R, Hartley M, Maxwell-Armstrong C, Mulvenna C, Phillips J, Yule A, Ahmed L, Clement KD, Craig N, Elseedawy E, Gorman D, Kane L, Livie J, Livie V, Moss E, Naasan A, Ravi F, Shields P, Zhu Y, Archer M, Cobley H, Dennis R, Downes C, Guevel B, Lamptey E, Murray H, Radhakrishnan A, Saravanabavan S, Sardar M, Shaw C, Tilliridou V, Wright R, Ye W, Alturki N, Helliwell R, Jones E, Kelly D, Lambotharan S, Scott K, Sivakumar R, Victor L, Boraluwe-Rallage H, Froggatt P, Haynes S, Hung YMA, Keyte A, Matthews L, Evans E, Haray P, John I, Mathivanan A, Morgan L, Oji O, Okorocha C, Rutherford A, Spiers H, Stageman N, Tsui A, Whitham R, Amoah-Arko A, Cecil E, Dietrich A, Fitzpatrick H, Guy C, Hair J, Hilton J, Jawad L, McAleer E, Taylor Z, Yap J, Akhbari M, Debnath D, Dhir T, Elbuzidi M, Elsaddig M, Glace S, Khawaja H, Koshy R, Lal K, Lobo L, McDermott A, Meredith J, Qamar MA, Vaidya A, Acquaah F, Barfi L, Carter N, Gnanappiragasam D, Ji C, Kaminski F, Lawday S, Mackay K, Sulaiman SK, Webb R, Ananthavarathan P, Dalal F, Farrar E, Hashemi R, Hossain M, Jiang J, Kiandee M, Lex J, Mason L, Matthews JH, McGeorge E, Modhwadia S, Pinkney T, Radotra A, Rickard L, Rodman L, Sales A, Tan KL, Bachi A, Bajwa DS, Battle J, Brown LR, Butler A, Calciu A, Davies E, Gardner I, Girdlestone T, Ikogho O, Keelan G, O'Loughlin P, Tam J, Elias J, Ngaage M, Thompson J, Bristow S, Brock E, Davis H, Pantelidou M, Sathiyakeerthy A, Singh K, Chaudhry A, Dickson G, Glen P, Gregoriou K, Hamid H, Mclean A, Mehtaji P, Neophytou G, Potts S, Belgaid DR, Burke J, Durno J, Ghailan N, Hanson M, Henshaw V, Nazir UR, Omar I, Riley BJ, Roberts J, Smart G, Van Winsen K, Bhatti A, Chan M, D'Auria M, Green S, Keshvala C, Li H, Maxwell-Armstrong C, Michaelidou M, Simmonds L, Smith C, Wimalathasan A, Abbas J, Cairns C, Chin YR, Connelly A, Moug S, Nair A, Svolkinas D, Coe P, Subar D, Wang H, Zaver V, Brayley J, Cookson P, Cunningham L, Gaukroger A, Ho M, Hough A, King J, O'Hagan D, Widdison A, Brown R, Brown B, Chavan A, Francis S, Hare L, Lund J, Malone N, Mavi B, McIlwaine A, Rangarajan S, Abuhussein N, Campbell HS, Daniels J, Fitzgerald I, Mansfield S, Pendrill A, Robertson D, Smart YW, Teng T, Yates J, Belgaumkar A, Katira A, Kossoff J, Kukran S, Laing C, Mathew B, Mohamed T, Myers S, Novell R, Phillips BL, Thomas M, Turlejski T, Turner S, Varcada M, Warren L, Wynell-Mayow W, Church R, Linley-Adams L, Osborn G, Saunders M, Spencer R, Srikanthan M, Tailor S, Tullett A, Ali M, Al-Masri S, Carr G, Ebhogiaye O, Heng S, Manivannan S, Manley J, McMillan LE, Peat C, Phillips B, Thomas S, Whewell H, Williams G, Bienias A, Cope EA, Courquin GR, Day L, Garner C, Gimson A, Harris C, Markham K, Moore T, Nadin T, Phillips C, Subratty SM, Brown K, Dada J, Durbacz M, Filipescu T, Harrison E, Kennedy ED, Khoo E, Kremel D, Lyell I, Pronin S, Tummon R, Ventre C, Walls L, Wootton E, Akhtar A, Davies E, El-Sawy D, Farooq M, Gaddah M, Griffiths H, Katsaiti I, Khadem N, Leong K, Williams I, Chean CS, Chudek D, Desai H, Ellerby N, Hammad A, Malla S, Murphy B, Oshin O, Popova P, Rana S, Ward T, Abbott TEF, Akpenyi O, Edozie F, El Matary R, English W, Jeyabaladevan S, Morgan C, Naidu V, Nicholls K, Peroos S, Prowle J, Sansome S, Torrance HD, Townsend D, Brecher J, Fung H, Kazmi Z, Outlaw P, Pursnani K, Ramanujam N, Razaq A, Sattar M, Sukumar S, Tan TSE, Chohan K, Dhuna S, Haq T, Kirby S, Lacy-Colson J, Logan P, Malik Q, McCann J, Mughal Z, Sadiq S, Sharif I, Shingles C, Simon A, Burnage S, Chan SSN, Craig ARJ, Duffield J, Dutta A, Eastwood M, Iqbal F, Mahmood F, Mahmood W, Patel C, Qadeer A, Robinson A, Rotundo A, Schade A, Slade RD, De Freitas M, Kinnersley H, McDowell E, Moens-Lecumberri S, Ramsden J, Rockall T, Wiffen L, Wright S, Bruce C, Francois V, Hamdan K, Limb C, Lunt AJ, Manley L, Marks M, Phillips CFE, Agnew CJF, Barr CJ, Benons N, Hart SJ, Kandage D, Krysztopik R, Mahalingam P, Mock J, Rajendran S, Stoddart MT, Clements B, Gillespie H, Lee S, McDougall R, Murray C, O'Loane R, Periketi S, Tan S, Amoah R, Bhudia R, Dudley B, Gilbert A, Griffiths B, Khan H, McKigney N, Roberts B, Samuel R, Seelarbokus A, Stubbing-Moore A, Thompson G, Williams P, Ahmed N, Akhtar R, Chandler E, Chappelow I, Gil H, Gower T, Kale A, Lingam G, Rutler L, Sellahewa C, Sheikh A, Stringer H, Taylor R, Aglan H, Ashraf MR, Choo S, Das E, Epstein J, Gentry R, Mills D, Poolovadoo Y, Ward N, Bull K, Cole A, Hack J, Khawari S, Lake C, Mandishona T, Perry R, Sleight S, Sultan S, Thornton T, Williams S, Arif T, Castle A, Chauhan P, Chesner R, Eilon T, Kamarajah S, Kambasha C, Lock L, Loka T, Mohammad F, Motahariasl S, Roper L, Sadhra SS, Sheikh A, Toma T, Wadood Q, Yip J, Ainger E, Busti S, Cunliffe L, Flamini T, Gaffing S, Moorcroft C, Peter M, Simpson L, Stokes E, Stott G, Wilson J, York J, Yousaf A, Borakati A, Brown M, Goaman A, Hodgson B, Ijeomah A, Iroegbu U, Kaur G, Lowe C, Mahmood S, Sattar Z, Sen P, Szuman A, Abbas N, Al-Ausi M, Anto N, Bhome R, Eccles L, Elliott J, Hughes EJ, Jones A, Karunatilleke AS, Knight JS, Manson CCF, Mekhail I, Michaels L, Noton TM, Okenyi E, Reeves T, Yasin IH, Banfield DA, Harris R, Lim D, Mason-Apps C, Roe T, Sandhu J, Shafiq N, Stickler E, Tam JP, Williams LM, Ainsworth P, Boualbanat Y, Doull C, Egan E, Evans L, Hassanin K, Ninkovic-Hall G, Odunlami W, Shergill M, Traish M, Cummings D, Kershaw S, Ong J, Reid F, Toellner H, Alwandi A, Amer M, George D, Haynes K, Hughes K, Peakall L, Premakumar Y, Punjabi N, Ramwell A, Sawkins H, Ashwood J, Baker A, Baron C, Bhide I, Blake E, De Cates C, Esmail R, Hosamuddin H, Kapp J, Nguru N, Raja M, Thomson F, Ahmed H, Aishwarya G, Al-Huneidi R, Ali S, Aziz R, Burke D, Clarke B, Kausar A, Maskill D, Mecia L, Myers L, Smith ACD, Walker G, Wroe N, Donohoe C, Gibbons D, Jordan P, Keogh C, Kiely A, Lalor P, McCrohan M, Powell C, Foley MP, Reynolds J, Silke E, Thorpe O, Kong JTH, White C, Ali Q, Dalrymple J, Ge Y, Khan H, Luo RS, Paine H, Paraskeva B, Parker L, Pillai K, Salciccioli J, Selvadurai S, Sonagara V, Springford LR, Tan L, Appleton S, Leadholm N, Zhang Y, Ahern D, Cotter M, Cremen S, Durrigan T, Flack V, Hrvacic N, Jones H, Jong B, Keane K, O'Connell PR, O'sullivan J, Pek G, Shirazi S, Barker C, Brown A, Carr W, Chen Y, Guillotte C, Harte J, Kokayi A, Lau K, McFarlane S, Morrison S, Broad J, Kenefick N, Makanji D, Printz V, Saito R, Thomas O, Breen H, Kirk S, Kong CH, O'Kane A, Eddama M, Engledow A, Freeman SK, Frost A, Goh C, Lee G, Poonawala R, Suri A, Taribagil P, Brown H, Christie S, Dean S, Gravell R, Haywood E, Holt F, Pilsworth E, Rabiu R, Roscoe HW, Shergill S, Sriram A, Sureshkumar A, Tan LC, Tanna A, Vakharia A, Bhullar S, Brannick S, Dunne E, Frere M, Kerin M, Kumar KM, Pratumsuwan T, Quek R, Salman M, Van Den Berg N, Wong C, Ahluwalia J, Bagga R, Borg CM, Calabria C, Draper A, Farwana M, Joyce H, Khan A, Mazza M, Pankin G, Sait MS, Sandhu N, Virani N, Wong J, Woodhams K, Croghan N, Ghag S, Hogg G, Ismail O, John N, Nadeem K, Naqi M, Noe SM, Sharma A, Tan S, Begum F, Best R, Collishaw A, Glasbey J, Golding D, Gwilym B, Harrison P, Jackman T, Lewis N, Luk YL, Porter T, Potluri S, Stechman M, Tate S, Thomas D, Walford B, Auld F, Bleakley A, Johnston S, Jones C, Khaw J, Milne S, O'Neill S, Singh KKR, Smith R, Swan A, Thorley N, Yalamarthi S, Yin ZD, Ali A, Balian V, Bana R, Clark K, Livesey C, McLachlan G, Mohammad M, Pranesh N, Richards C, Ross F, Sajid M, Brooke M, Francombe J, Gresly J, Hutchinson S, Kerrigan K, Matthews E, Nur S, Parsons L, Sandhu A, Vyas M, White F, Zulkifli A, Zuzarte L, Al-Mousawi A, Arya J, Azam S, Yahaya AA, Gill K, Hallan R, Hathaway C, Leptidis I, McDonagh L, Mitrasinovic S, Mushtaq N, Pang N, Peiris GB, Rinkoff S, Chan L, Christopher E, Farhan-Alanie MMH, Gonzalez-Ciscar A, Graham CJ, Lim H, McLean KA, Paterson HM, Rogers A, Roy C, Rutherford D, Smith F, Zubikarai G, Al-Khudairi R, Bamford M, Chang M, Cheng J, Hedley C, Joseph R, Mitchell B, Perera S, Rothwell L, Siddiqui A, Smith J, Taylor K, Wright OW, Baryan HK, Boyd G, Conchie H, Cox L, Davies J, Gardner S, Hill N, Krishna K, Lakin F, Scotcher S, Alberts J, Asad M, Barraclough J, Campbell A, Marshall D, Wakeford W, Cronbach P, D'Souza F, Gammeri E, Houlton J, Hall M, Kethees A, Patel R, Perera M, Prowle J, Shaid M, Webb E, Beattie S, Chadwick M, El-Taji O, Haddad S, Mann M, Patel M, Popat K, Rimmer L, Riyat H, Smith H, Anandarajah C, Cipparrone M, Desai K, Gao C, Goh ET, Howlader M, Jeffreys N, Karmarkar A, Mathew G, Mukhtar H, Ozcan E, Renukanthan A, Sarens N, Sinha C, Woolley A, Bogle R, Komolafe O, Loo F, Waugh D, Zeng R, Crewe A, Mathias J, Mills A, Owen A, Prior A, Saunders I, Baker A, Crilly L, McKeon J, Ubhi HK, Adeogun A, Carr R, Davison C, Devalia S, Hayat A, Karsan RB, Osborne C, Scott K, Weegenaar C, Wijeyaratne M, Babatunde F, Barnor-Ahiaku E, Beattie G, Chitsabesan P, Dixon O, Hall N, Ilenkovan N, Mackrell T, Nithianandasivam N, Orr J, Palazzo F, Saad M, Sandland-Taylor L, Sherlock J, Ashdown T, Chandler S, Garsaa T, Lloyd J, Loh SY, Ng S, Perkins C, Powell-Chandler A, Smith F, Underhill R. Perioperative intravenous contrast administration and the incidence of acute kidney injury after major gastrointestinal surgery: prospective, multicentre cohort study. Br J Surg 2020; 107:1023-1032. [PMID: 32026470 DOI: 10.1002/bjs.11453] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2019] [Revised: 09/21/2019] [Accepted: 11/08/2019] [Indexed: 01/14/2023]
Abstract
BACKGROUND This study aimed to determine the impact of preoperative exposure to intravenous contrast for CT and the risk of developing postoperative acute kidney injury (AKI) in patients undergoing major gastrointestinal surgery. METHODS This prospective, multicentre cohort study included adults undergoing gastrointestinal resection, stoma reversal or liver resection. Both elective and emergency procedures were included. Preoperative exposure to intravenous contrast was defined as exposure to contrast administered for the purposes of CT up to 7 days before surgery. The primary endpoint was the rate of AKI within 7 days. Propensity score-matched models were adjusted for patient, disease and operative variables. In a sensitivity analysis, a propensity score-matched model explored the association between preoperative exposure to contrast and AKI in the first 48 h after surgery. RESULTS A total of 5378 patients were included across 173 centres. Overall, 1249 patients (23·2 per cent) received intravenous contrast. The overall rate of AKI within 7 days of surgery was 13·4 per cent (718 of 5378). In the propensity score-matched model, preoperative exposure to contrast was not associated with AKI within 7 days (odds ratio (OR) 0·95, 95 per cent c.i. 0·73 to 1·21; P = 0·669). The sensitivity analysis showed no association between preoperative contrast administration and AKI within 48 h after operation (OR 1·09, 0·84 to 1·41; P = 0·498). CONCLUSION There was no association between preoperative intravenous contrast administered for CT up to 7 days before surgery and postoperative AKI. Risk of contrast-induced nephropathy should not be used as a reason to avoid contrast-enhanced CT.
Collapse
|
37
|
Bisson C, Castellano T, Zhao D, Johnston S, Gunderson C. Impact of race on management, treatment, and outcomes in vulvar cancer. Gynecol Oncol 2020. [DOI: 10.1016/j.ygyno.2019.11.103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
38
|
Vaughan-Shaw PG, Zgaga L, Ooi LY, Theodoratou E, Timofeeva M, Svinti V, Walker M, O'Sullivan F, Ewing A, Johnston S, Din FVN, Campbell H, Farrington SM, Dunlop MG. Low plasma vitamin D is associated with adverse colorectal cancer survival after surgical resection, independent of systemic inflammatory response. Gut 2020; 69:103-111. [PMID: 31023832 PMCID: PMC6943245 DOI: 10.1136/gutjnl-2018-317922] [Citation(s) in RCA: 31] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/13/2018] [Revised: 03/04/2019] [Accepted: 03/26/2019] [Indexed: 12/31/2022]
Abstract
OBJECTIVE We assessed the effect of surgical resection of colorectal cancer (CRC) on perioperative plasma vitamin D (25OHD) and C-reactive protein (CRP) level. We investigated the relationship between circulating vitamin D level and CRC survival. DESIGN We sequentially sampled 92 patients undergoing CRC resection, and measured plasma 25OHD and CRP. For survival analyses, we assayed 25OHD and CRP in two temporally distinct CRC patient cohorts (n=2006, n=2100) and investigated the association between survival outcome, circulating vitamin D and systemic inflammatory response. RESULTS Serial sampling revealed a postoperative fall (mean 17.3 nmol/L; p=3.6e-9) in plasma 25OHD (nadir days 1-2). CRP peaked 3-5 days postoperatively (143.1 mg/L; p=1.4e-12), yet the postoperative fall in 25OHD was independent of CRP. In cohort analyses, 25OHD was lower in the 12 months following operation (mean=48.8 nmol/L) than preoperatively (54.8 nmol/L; p=1.2e-5) recovering after 24 months (52.2 nmol/L; p=0.002). Survival analysis in American Joint Committee on Cancer stages I-III demonstrated associations between 25OHD tertile and CRC mortality (HR=0.69; 95% CI 0.46 to 0.91) and all-cause mortality (HR=0.68; 95% CI 0.50 to 0.85), and was independent of CRP. We observed interaction effects between plasma 25OHD and rs11568820 genotype (functional VDR polymorphism) with a strong protective effect of higher 25OHD only in patients with GG genotype (HR=0.51; 95% CI 0.21 to 0.81). We developed an online tool for predicted survival (https://apps.igmm.ed.ac.uk/mortalityCalculator/) that incorporates 25OHD with clinically useful predictive performance (area under the curve 0.77). CONCLUSIONS CRC surgery induces a fall in circulating 25OHD. Plasma 25OHD level is a prognostic biomarker with low 25OHD associated with poorer survival, particularly in those with rs11568820 GG genotype. A randomised trial of vitamin D supplementation after CRC surgery has compelling rationale.
Collapse
Affiliation(s)
- P G Vaughan-Shaw
- Cancer Research UK Edinburgh Centre and MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
| | - L Zgaga
- Department of Public Health and Primary Care, Trinity College Dublin, Dublin 24, Republic of Ireland
| | - L Y Ooi
- Cancer Research UK Edinburgh Centre and MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
| | - E Theodoratou
- Centre for Global Health Research, Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK
- Cancer Research UK Edinburgh Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
| | - M Timofeeva
- Cancer Research UK Edinburgh Centre and MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
| | - V Svinti
- Cancer Research UK Edinburgh Centre and MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
| | - M Walker
- Cancer Research UK Edinburgh Centre and MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
| | - F O'Sullivan
- Department of Public Health and Primary Care, Trinity College Dublin, Dublin 24, Republic of Ireland
| | - A Ewing
- Cancer Research UK Edinburgh Centre and MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
| | - S Johnston
- Specialist Endocrine Laboratory, NHS Greater Glasgow and Clyde, Glasgow, UK
| | - F V N Din
- Cancer Research UK Edinburgh Centre and MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
| | - H Campbell
- Centre for Global Health Research, Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK
| | - S M Farrington
- Cancer Research UK Edinburgh Centre and MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
| | - M G Dunlop
- Cancer Research UK Edinburgh Centre and MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
| |
Collapse
|
39
|
Rugo HS, Diéras V, Gelmon KA, Finn RS, Slamon DJ, Martin M, Neven P, Shparyk Y, Mori A, Lu DR, Bhattacharyya H, Bartlett CHUANG, Iyer S, Johnston S, Ettl J, Harbeck N. Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. Ann Oncol 2019; 29:888-894. [PMID: 29360932 PMCID: PMC5913649 DOI: 10.1093/annonc/mdy012] [Citation(s) in RCA: 90] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Background Patient-reported outcomes are integral in benefit-risk assessments of new treatment regimens. The PALOMA-2 study provides the largest body of evidence for patient-reported health-related quality of life (QOL) for patients with metastatic breast cancer (MBC) receiving first-line endocrine-based therapy (palbociclib plus letrozole and letrozole alone). Patients and methods Treatment-naïve postmenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) MBC were randomized 2 : 1 to palbociclib plus letrozole (n = 444) or placebo plus letrozole (n = 222). Patient-reported outcomes were assessed at baseline, day 1 of cycles 2 and 3, and day 1 of every other cycle from cycle 5 using the Functional Assessment of Cancer Therapy (FACT)-Breast and EuroQOL 5 dimensions (EQ-5D) questionnaires. Results As of 26 February 2016, the median duration of follow-up was 23 months. Baseline scores were comparable between the two treatment arms. No significant between-arm differences were observed in change from baseline in FACT-Breast Total, FACT-General Total, or EQ-5D scores. Significantly greater improvement in pain scores was observed in the palbociclib plus letrozole arm (-0.256 versus -0.098; P = 0.0183). In both arms, deterioration of FACT-Breast Total score was significantly delayed in patients without progression versus those with progression and patients with partial or complete response versus those without. No significant difference was observed in FACT-Breast and EQ-5D index scores in patients with and without neutropenia. Conclusions Overall, women with MBC receiving first-line endocrine therapy have a good QOL. The addition of palbociclib to letrozole maintains health-related QOL and improves pain scores in treatment-naïve postmenopausal patients with ER+/HER2- MBC compared with letrozole alone. Significantly greater delay in deterioration of health-related QOL was observed in patients without progression versus those who progressed and in patients with an objective response versus non-responders. ClinicalTrials.gov: NCT01740427 (https://clinicaltrials.gov/ct2/show/NCT01740427).
Collapse
Affiliation(s)
- H S Rugo
- Department of Medicine (Hematology/Oncology), University of California San Francisco Comprehensive Cancer Center, San Francisco, USA.
| | - V Diéras
- Department of Medical Oncology, Institut Curie, Paris, France
| | - K A Gelmon
- Department of Medical Oncology, British Columbia Cancer Agency-Vancouver Centre, Vancouver, Canada
| | - R S Finn
- Division of Hematology/Oncology, University of California, Los Angeles, USA
| | - D J Slamon
- Division of Hematology/Oncology, University of California, Los Angeles, USA
| | - M Martin
- Medical Oncology Service, Instituto de Investigación Sanitaria Gregorio Marañón, GEICAM, Universidad Complutense, Madrid, Spain
| | - P Neven
- Department of Oncology, Universitair Ziekenhuis Leuven-Campus Gasthuisberg, Leuven, Belgium
| | - Y Shparyk
- Department of Chemotherapy, Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine
| | - A Mori
- Global Product Developmen, Clinical, Pfizer s.r.l., Milan, Italy
| | - D R Lu
- Global Product Developmen, Statistics, Pfizer Inc., La Jolla, USA
| | | | | | - S Iyer
- Global Outcomes and Evidence, Pfizer Inc., New York, USA
| | - S Johnston
- Department of Medical Oncology, The Royal Marsden NHS Foundation, London, UK
| | - J Ettl
- Department of Obstetrics and Gynecology, Frauenklinik und Poliklinik Klinikum Rechts der Isar, Technische Universität München, München, Germany
| | - N Harbeck
- Department of Obstetrics and Gynecology, Brustzentrum der Universität München (LMU), München, Germany
| |
Collapse
|
40
|
Martín M, Johnston S, Huober J, Di Leo A, Sohn J, Andre V, Martin H, Hardebeck M, Goetz M. MONARCH 3: Updated time to chemotherapy and disease progression following abemaciclib plus aromatase inhibitor (AI) in HR+, HER2- advanced breast cancer (ABC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz242.021] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
41
|
Tan M, Johnston S, Nicholls J, Gompels M. Dual therapy with renally adjusted lamivudine and dolutegravir: a switch strategy to manage comorbidity and toxicity in older, suppressed patients? HIV Med 2019; 20:634-637. [PMID: 31338933 PMCID: PMC6790693 DOI: 10.1111/hiv.12781] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/10/2019] [Indexed: 11/27/2022]
Abstract
OBJECTIVES The aim of the study was to evaluate the efficacy of dual therapy with lamivudine (3TC), with dose adjustment for renal function, and dolutegravir (DTG) in a subgroup of patients fully suppressed on treatment who were switched because of concerns about comorbidity and toxicity on their current triple drug regimen. METHODS A retrospective evaluation of clinical and pathological parameters from an electronic patient record from a single centre was carried out. RESULTS There were no virological failures in 52 patients with a median age of 60.5 years. The median duration of follow-on dual therapy was 2.29 years (28 months; range 1.10-3.34 years). In 25 of 52 (48%) cases, the dose of 3TC was adjusted taking into account reduced renal function, and none of these patients experienced virological failure. Four additional patients discontinued early, because of side effects of the switch, with no failure. CONCLUSIONS This retrospective review suggests that 3TC and DTG may be effective in controlling viral load in older patients with comorbidities. This regimen appears to be a useful option in the context of comorbidities (including renal impairment) and polypharmacy in older patients. However, this review has been conducted in one centre and in a small population of patients. Therefore, further multicentre trials involving larger populations of patients are needed.
Collapse
Affiliation(s)
- M Tan
- University of Bristol Medical School, Bristol, UK
| | | | | | - M Gompels
- North Bristol NHS Trust, Bristol, UK
| |
Collapse
|
42
|
Hattawy M, Baltzell NA, Dupré R, Bültmann S, De Vita R, El Alaoui A, El Fassi L, Egiyan H, Girod FX, Guidal M, Hafidi K, Jenkins D, Liuti S, Perrin Y, Stepanyan S, Torayev B, Voutier E, Adhikari S, Angelini G, Ayerbe Gayoso C, Barion L, Battaglieri M, Bedlinskiy I, Biselli AS, Bossù F, Brooks W, Cao F, Carman DS, Celentano A, Chatagnon P, Chetry T, Ciullo G, Clark L, Cole PL, Contalbrigo M, Crede V, D'Angelo A, Dashyan N, De Sanctis E, Defurne M, Deur A, Diehl S, Djalali C, Ehrhart M, Eugenio P, Fegan S, Filippi A, Forest TA, Fradi A, Garçon M, Gavalian G, Gevorgyan N, Gilfoyle GP, Giovanetti KL, Golovatch E, Gothe RW, Griffioen KA, Harrison N, Hauenstein F, Hayward TB, Heddle D, Hicks K, Holtrop M, Ilieva Y, Ireland DG, Isupov EL, Jo HS, Johnston S, Keller D, Khachatryan G, Khachatryan M, Khanal A, Khandaker M, Kim CW, Kim W, Klein FJ, Kubarovsky V, Kuhn SE, Lanza L, L Kabir M, Lenisa P, Livingston K, MacGregor IJD, Marchand D, Markov N, Mayer M, McKinnon B, Meziani ZE, Mineeva T, Mirazita M, Montgomery RA, Munoz Camacho C, Nadel-Turonski P, Niccolai S, Ostrovidov AI, Pappalardo LL, Paremuzyan R, Pasyuk E, Pogorelko O, Poudel J, Prok Y, Protopopescu D, Ripani M, Riser D, Rizzo A, Rosner G, Rossi P, Sabatié F, Salgado C, Schumacher RA, Sharabian YG, Skorodumina I, Sokhan D, Soto O, Sparveris N, Strauch S, Taiuti M, Tan JA, Tyler N, Ungaro M, Voskanyan H, Wang R, Watts DP, Wei X, Weinstein LB, Wood MH, Zachariou N, Zhang J, Zhao ZW. Exploring the Structure of the Bound Proton with Deeply Virtual Compton Scattering. Phys Rev Lett 2019; 123:032502. [PMID: 31386486 DOI: 10.1103/physrevlett.123.032502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/19/2018] [Revised: 03/12/2019] [Indexed: 06/10/2023]
Abstract
In the past two decades, deeply virtual Compton scattering of electrons has been successfully used to advance our knowledge of the partonic structure of the free proton and investigate correlations between the transverse position and the longitudinal momentum of quarks inside the nucleon. Meanwhile, the structure of bound nucleons in nuclei has been studied in inclusive deep-inelastic lepton scattering experiments off nuclear targets, showing a significant difference in longitudinal momentum distribution of quarks inside the bound nucleon, known as the EMC effect. In this Letter, we report the first beam spin asymmetry (BSA) measurement of exclusive deeply virtual Compton scattering off a proton bound in ^{4}He. The data used here were accumulated using a 6 GeV longitudinally polarized electron beam incident on a pressurized ^{4}He gaseous target placed within the CLAS spectrometer in Hall-B at the Thomas Jefferson National Accelerator Facility. The azimuthal angle (ϕ) dependence of the BSA was studied in a wide range of virtual photon and scattered proton kinematics. The Q^{2}, x_{B}, and t dependencies of the BSA on the bound proton are compared with those on the free proton. In the whole kinematical region of our measurements, the BSA on the bound proton is smaller by 20% to 40%, indicating possible medium modification of its partonic structure.
Collapse
Affiliation(s)
- M Hattawy
- Argonne National Laboratory, Argonne, Illinois 60439, USA
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - N A Baltzell
- Argonne National Laboratory, Argonne, Illinois 60439, USA
- Old Dominion University, Norfolk, Virginia 23529, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - R Dupré
- Argonne National Laboratory, Argonne, Illinois 60439, USA
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - S Bültmann
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - R De Vita
- INFN, Sezione di Genova, 16146 Genova, Italy
| | - A El Alaoui
- Argonne National Laboratory, Argonne, Illinois 60439, USA
- Universidad Técnica Federico Santa María, Casilla 110-V Valparaíso, Chile
| | - L El Fassi
- Argonne National Laboratory, Argonne, Illinois 60439, USA
- Mississippi State University, Mississippi State, Mississippi 39762-5167, USA
| | - H Egiyan
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - F X Girod
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M Guidal
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - K Hafidi
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - D Jenkins
- Virginia Tech, Blacksburg, Virginia 24061-0435, USA
| | - S Liuti
- University of Virginia, Charlottesville, Virginia 22901, USA
| | - Y Perrin
- LPSC, Université Grenoble-Alpes, CNRS/IN2P3, 38026 Grenoble, France
| | - S Stepanyan
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - B Torayev
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - E Voutier
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
- LPSC, Université Grenoble-Alpes, CNRS/IN2P3, 38026 Grenoble, France
| | - S Adhikari
- Florida International University, Miami, Florida 33199, USA
| | | | - C Ayerbe Gayoso
- College of William and Mary, Williamsburg, Virginia 23187-8795, USA
| | - L Barion
- INFN, Sezione di Ferrara, 44100 Ferrara, Italy
| | | | - I Bedlinskiy
- Institute of Theoretical and Experimental Physics, Moscow, 117259, Russia
| | - A S Biselli
- Fairfield University, Fairfield Connecticut 06824, USA
| | - F Bossù
- IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - W Brooks
- Universidad Técnica Federico Santa María, Casilla 110-V Valparaíso, Chile
| | - F Cao
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - D S Carman
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A Celentano
- INFN, Sezione di Genova, 16146 Genova, Italy
| | - P Chatagnon
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - T Chetry
- Ohio University, Athens, Ohio 45701, USA
| | - G Ciullo
- Universita' di Ferrara, 44121 Ferrara, Italy
- INFN, Sezione di Ferrara, 44100 Ferrara, Italy
| | - L Clark
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - P L Cole
- Idaho State University, Pocatello, Idaho 83209, USA
- Lamar University, 4400 MLK Boulevard, P.O. Box 10009, Beaumont, Texas 77710, USA
| | | | - V Crede
- Florida State University, Tallahassee, Florida 32306, USA
| | - A D'Angelo
- INFN, Sezione di Roma Tor Vergata, 00133 Rome, Italy
- Universita' di Roma Tor Vergata, 00133 Rome, Italy
| | - N Dashyan
- Yerevan Physics Institute, 375036 Yerevan, Armenia
| | - E De Sanctis
- INFN, Laboratori Nazionali di Frascati, 00044 Frascati, Italy
| | - M Defurne
- IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - A Deur
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S Diehl
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - C Djalali
- Ohio University, Athens, Ohio 45701, USA
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - M Ehrhart
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - P Eugenio
- Florida State University, Tallahassee, Florida 32306, USA
| | - S Fegan
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - A Filippi
- INFN, Sezione di Torino, 10125 Torino, Italy
| | - T A Forest
- Idaho State University, Pocatello, Idaho 83209, USA
| | - A Fradi
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - M Garçon
- IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - G Gavalian
- Old Dominion University, Norfolk, Virginia 23529, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - N Gevorgyan
- Yerevan Physics Institute, 375036 Yerevan, Armenia
| | - G P Gilfoyle
- University of Richmond, Richmond, Virginia 23173, USA
| | - K L Giovanetti
- James Madison University, Harrisonburg, Virginia 22807, USA
| | - E Golovatch
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, 119234 Moscow, Russia
| | - R W Gothe
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - K A Griffioen
- College of William and Mary, Williamsburg, Virginia 23187-8795, USA
| | - N Harrison
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - F Hauenstein
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - T B Hayward
- College of William and Mary, Williamsburg, Virginia 23187-8795, USA
| | - D Heddle
- Christopher Newport University, Newport News, Virginia 23606, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - K Hicks
- Ohio University, Athens, Ohio 45701, USA
| | - M Holtrop
- University of New Hampshire, Durham, New Hampshire 03824-3568, USA
| | - Y Ilieva
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - D G Ireland
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - E L Isupov
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, 119234 Moscow, Russia
| | - H S Jo
- Kyungpook National University, Daegu 41566, Republic of Korea
| | - S Johnston
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - D Keller
- Ohio University, Athens, Ohio 45701, USA
- University of Virginia, Charlottesville, Virginia 22901, USA
| | | | - M Khachatryan
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - A Khanal
- Florida International University, Miami, Florida 33199, USA
| | - M Khandaker
- Norfolk State University, Norfolk, Virginia 23504, USA
| | - C W Kim
- The George Washington University, Washington, DC 20052, USA
| | - W Kim
- Kyungpook National University, Daegu 41566, Republic of Korea
| | - F J Klein
- Catholic University of America, Washington, DC 20064, USA
| | - V Kubarovsky
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S E Kuhn
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - L Lanza
- INFN, Sezione di Roma Tor Vergata, 00133 Rome, Italy
| | - M L Kabir
- Mississippi State University, Mississippi State, Mississippi 39762-5167, USA
| | - P Lenisa
- INFN, Sezione di Ferrara, 44100 Ferrara, Italy
| | - K Livingston
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | | | - D Marchand
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - N Markov
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - M Mayer
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - B McKinnon
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - Z E Meziani
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - T Mineeva
- Universidad Técnica Federico Santa María, Casilla 110-V Valparaíso, Chile
| | - M Mirazita
- INFN, Laboratori Nazionali di Frascati, 00044 Frascati, Italy
| | | | - C Munoz Camacho
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - P Nadel-Turonski
- Catholic University of America, Washington, DC 20064, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S Niccolai
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - A I Ostrovidov
- Florida State University, Tallahassee, Florida 32306, USA
| | | | - R Paremuzyan
- University of New Hampshire, Durham, New Hampshire 03824-3568, USA
- Yerevan Physics Institute, 375036 Yerevan, Armenia
| | - E Pasyuk
- Arizona State University, Tempe, Arizona 85287-1504, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - O Pogorelko
- Institute of Theoretical and Experimental Physics, Moscow, 117259, Russia
| | - J Poudel
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - Y Prok
- Old Dominion University, Norfolk, Virginia 23529, USA
- University of Virginia, Charlottesville, Virginia 22901, USA
| | | | - M Ripani
- INFN, Sezione di Genova, 16146 Genova, Italy
| | - D Riser
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - A Rizzo
- INFN, Sezione di Roma Tor Vergata, 00133 Rome, Italy
- Universita' di Roma Tor Vergata, 00133 Rome, Italy
| | - G Rosner
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - P Rossi
- INFN, Laboratori Nazionali di Frascati, 00044 Frascati, Italy
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - F Sabatié
- IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - C Salgado
- Norfolk State University, Norfolk, Virginia 23504, USA
| | - R A Schumacher
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - Y G Sharabian
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - Iu Skorodumina
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, 119234 Moscow, Russia
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - D Sokhan
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - O Soto
- Universidad Técnica Federico Santa María, Casilla 110-V Valparaíso, Chile
| | - N Sparveris
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - S Strauch
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - M Taiuti
- Universitá di Genova, 16146 Genova, Italy
| | - J A Tan
- Kyungpook National University, Daegu 41566, Republic of Korea
| | - N Tyler
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - M Ungaro
- University of Connecticut, Storrs, Connecticut 06269, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - H Voskanyan
- Yerevan Physics Institute, 375036 Yerevan, Armenia
| | - R Wang
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - D P Watts
- University of York, York YO10 5DD, United Kingdom
| | - X Wei
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - L B Weinstein
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - M H Wood
- Canisius College, Buffalo, New York, USA
| | - N Zachariou
- University of York, York YO10 5DD, United Kingdom
| | - J Zhang
- Old Dominion University, Norfolk, Virginia 23529, USA
- University of Virginia, Charlottesville, Virginia 22901, USA
| | - Z W Zhao
- Duke University, Durham, North Carolina 27708-0305, USA
- University of South Carolina, Columbia, South Carolina 29208, USA
| |
Collapse
|
43
|
Irfan T, Turkes F, Asare B, Mohammed K, Osin P, Nerurkar A, Smith I, Parton M, Johnston S, Turner N, Okines A. Clinical Outcomes in Triple-negative Lobular Breast Cancer: a Single-institution Experience. Clin Oncol (R Coll Radiol) 2019. [DOI: 10.1016/j.clon.2019.03.021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
44
|
Johnston S, MacDermid E, Winter M, Canagasingham B, Shakeshaft AJ. Rectourethral fistula: the result of an unusual sequence of events. Br J Hosp Med (Lond) 2019; 80:352-353. [PMID: 31180780 DOI: 10.12968/hmed.2019.80.6.352] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Sarah Johnston
- General Surgical Unaccredited Registrar, Department of Colorectal Surgery, Nepean Hospital, Sydney, Australia
| | - Ewan MacDermid
- General Surgical Registrar, Department of Colorectal Surgery, Nepean Hospital, Sydney, Australia
| | - Matthew Winter
- Urology Fellow, Department of Urology, Nepean Hospital, Sydney, Australia
| | | | - Anthony J Shakeshaft
- Colorectal Surgeon, Department of Colorectal Surgery, Nepean Hospital, Sydney, Australia
| |
Collapse
|
45
|
Connor KR, Pritchett RC, Pritchett KL, Katica CP, McCall GE, Yee ST, Cheng RH, Ulrich B, Adams N, Johnston S. Effects of Two Cooling Strategies on Performance and Perceptual Measures Among Athletes with an SCI. Med Sci Sports Exerc 2019. [DOI: 10.1249/01.mss.0000561360.39917.3d] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
46
|
Roy P, Park S, Crede V, Anisovich AV, Klempt E, Nikonov VA, Sarantsev AV, Wei NC, Huang F, Nakayama K, Adhikari KP, Adhikari S, Angelini G, Avakian H, Barion L, Battaglieri M, Bedlinskiy I, Biselli AS, Boiarinov S, Briscoe WJ, Brock J, Brooks WK, Burkert VD, Cao F, Carlin C, Carman DS, Celentano A, Chatagnon P, Chetry T, Ciullo G, Cole PL, Contalbrigo M, Cortes O, D'Angelo A, Dashyan N, De Vita R, De Sanctis E, Deur A, Diehl S, Djalali C, Dugger M, Dupre R, Duran B, Egiyan H, Ehrhart M, El Alaoui A, El Fassi L, Eugenio P, Fegan S, Filippi A, Fradi A, Gilfoyle GP, Girod FX, Golovatch E, Gothe RW, Griffioen KA, Guidal M, Guo L, Hafidi K, Hanretty C, Harrison N, Hattawy M, Hayward TB, Heddle D, Hicks K, Holtrop M, Ilieva Y, Ireland DG, Ishkhanov BS, Isupov EL, Jenkins D, Jo HS, Johnston S, Joosten S, Kabir ML, Keith CD, Keller D, Khachatryan G, Khachatryan M, Khanal A, Khandaker M, Kim A, Kim W, Klein FJ, Kubarovsky V, Kuleshov SV, Kunkel MC, Lanza L, Lenisa P, Livingston K, MacGregor IJD, Marchand D, McKinnon B, Meekins DG, Meyer CA, Mineeva T, Mokeev V, Montgomery RA, Movsisyan A, Munoz Camacho C, Nadel-Turonski P, Niccolai S, Niculescu G, Osipenko M, Ostrovidov AI, Paolone M, Pappalardo LL, Paremuzyan R, Pasyuk E, Payette D, Phelps W, Pierce J, Pogorelko O, Prok Y, Protopopescu D, Raue BA, Ripani M, Riser D, Ritchie BG, Rizzo A, Rosner G, Sabatié F, Salgado C, Schumacher RA, Seely ML, Sharabian YG, Shrestha U, Skorodumina I, Sokhan D, Soto O, Sparveris N, Strakovsky II, Strauch S, Taiuti M, Tan JA, Torayev B, Tyler N, Ungaro M, Voskanyan H, Voutier E, Walford NK, Wang R, Watts DP, Wei X, Wood MH, Zachariou N, Zhang J, Zhao ZW. First Measurements of the Double-Polarization Observables F, P, and H in ω Photoproduction off Transversely Polarized Protons in the N^{*} Resonance Region. Phys Rev Lett 2019; 122:162301. [PMID: 31075002 DOI: 10.1103/physrevlett.122.162301] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/10/2018] [Revised: 03/12/2019] [Indexed: 06/09/2023]
Abstract
First measurements of double-polarization observables in ω photoproduction off the proton are presented using transverse target polarization and data from the CEBAF Large Acceptance Spectrometer (CLAS) FROST experiment at Jefferson Lab. The beam-target asymmetry F has been measured using circularly polarized, tagged photons in the energy range 1200-2700 MeV, and the beam-target asymmetries H and P have been measured using linearly polarized, tagged photons in the energy range 1200-2000 MeV. These measurements significantly increase the database on polarization observables. The results are included in two partial-wave analyses and reveal significant contributions from several nucleon (N^{*}) resonances. In particular, contributions from new N^{*} resonances listed in the Review of Particle Properties are observed, which aid in reaching the goal of mapping out the nucleon resonance spectrum.
Collapse
Affiliation(s)
- P Roy
- Florida State University, Tallahassee, Florida 32306, USA
| | - S Park
- Florida State University, Tallahassee, Florida 32306, USA
| | - V Crede
- Florida State University, Tallahassee, Florida 32306, USA
| | - A V Anisovich
- Helmholtz-Institut für Strahlen- und Kernphysik, Universität Bonn, 53115 Bonn, Germany
- NRC "Kurchatov Institute," PNPI, 188300, Gatchina, Russia
| | - E Klempt
- Helmholtz-Institut für Strahlen- und Kernphysik, Universität Bonn, 53115 Bonn, Germany
| | - V A Nikonov
- Helmholtz-Institut für Strahlen- und Kernphysik, Universität Bonn, 53115 Bonn, Germany
- NRC "Kurchatov Institute," PNPI, 188300, Gatchina, Russia
| | - A V Sarantsev
- Helmholtz-Institut für Strahlen- und Kernphysik, Universität Bonn, 53115 Bonn, Germany
- NRC "Kurchatov Institute," PNPI, 188300, Gatchina, Russia
| | - N C Wei
- Zhengzhou University, Zhengzhou, Henan 450001, China
- School of Nuclear Science and Technology, University of Chinese Academy of Sciences, Beijing 100049, China
| | - F Huang
- School of Nuclear Science and Technology, University of Chinese Academy of Sciences, Beijing 100049, China
| | - K Nakayama
- University of Georgia, Athens, Georgia 30602, USA
| | - K P Adhikari
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - S Adhikari
- Florida International University, Miami, Florida 33199, USA
| | - G Angelini
- The George Washington University, Washington, DC 20052, USA
| | - H Avakian
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - L Barion
- INFN, Sezione di Ferrara, 44100 Ferrara, Italy
| | | | - I Bedlinskiy
- Institute of Theoretical and Experimental Physics, Moscow, 117259, Russia
| | - A S Biselli
- Fairfield University, Fairfield, Connecticut 06824, USA
| | - S Boiarinov
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - W J Briscoe
- The George Washington University, Washington, DC 20052, USA
| | - J Brock
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - W K Brooks
- Universidad Técnica Federico Santa María, Casilla 110-V Valparaíso, Chile
| | - V D Burkert
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - F Cao
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - C Carlin
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - D S Carman
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A Celentano
- INFN, Sezione di Genova, 16146 Genova, Italy
| | - P Chatagnon
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - T Chetry
- Ohio University, Athens, Ohio 45701, USA
| | - G Ciullo
- Università di Ferrara, 44121 Ferrara, Italy
- INFN, Sezione di Ferrara, 44100 Ferrara, Italy
| | - P L Cole
- Idaho State University, Pocatello, Idaho 83209, USA
- Lamar University, 4400 MLK Blvd, P.O. Box 10009, Beaumont, Texas 77710, USA
| | | | - O Cortes
- The George Washington University, Washington, DC 20052, USA
| | - A D'Angelo
- INFN, Sezione di Roma Tor Vergata, 00133 Rome, Italy
- Università di Roma Tor Vergata, 00133 Rome, Italy
| | - N Dashyan
- Yerevan Physics Institute, 375036 Yerevan, Armenia
| | - R De Vita
- INFN, Sezione di Genova, 16146 Genova, Italy
| | - E De Sanctis
- INFN, Laboratori Nazionali di Frascati, 00044 Frascati, Italy
| | - A Deur
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S Diehl
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - C Djalali
- Ohio University, Athens, Ohio 45701, USA
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - M Dugger
- Arizona State University, Tempe, Arizona 85287-1504, USA
| | - R Dupre
- Argonne National Laboratory, Argonne, Illinois 60439, USA
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - B Duran
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - H Egiyan
- University of New Hampshire, Durham, New Hampshire 03824-3568, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M Ehrhart
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - A El Alaoui
- Universidad Técnica Federico Santa María, Casilla 110-V Valparaíso, Chile
| | - L El Fassi
- Mississippi State University, Mississippi State, Mississippi 39762-5167, USA
| | - P Eugenio
- Florida State University, Tallahassee, Florida 32306, USA
| | - S Fegan
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - A Filippi
- INFN, Sezione di Torino, 10125 Torino, Italy
| | - A Fradi
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - G P Gilfoyle
- University of Richmond, Richmond, Virginia 23173, USA
| | - F X Girod
- IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - E Golovatch
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, 119234 Moscow, Russia
| | - R W Gothe
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - K A Griffioen
- College of William and Mary, Williamsburg, Virginia 23187-8795, USA
| | - M Guidal
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - L Guo
- Florida International University, Miami, Florida 33199, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - K Hafidi
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - C Hanretty
- Florida State University, Tallahassee, Florida 32306, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - N Harrison
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M Hattawy
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - T B Hayward
- College of William and Mary, Williamsburg, Virginia 23187-8795, USA
| | - D Heddle
- Christopher Newport University, Newport News, Virginia 23606, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - K Hicks
- Ohio University, Athens, Ohio 45701, USA
| | - M Holtrop
- University of New Hampshire, Durham, New Hampshire 03824-3568, USA
| | - Y Ilieva
- The George Washington University, Washington, DC 20052, USA
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - D G Ireland
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - B S Ishkhanov
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, 119234 Moscow, Russia
| | - E L Isupov
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, 119234 Moscow, Russia
| | - D Jenkins
- Virginia Tech, Blacksburg, Virginia 24061-0435, USA
| | - H S Jo
- Kyungpook National University, Daegu 41566, Republic of Korea
| | - S Johnston
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - S Joosten
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - M L Kabir
- Mississippi State University, Mississippi State, Mississippi 39762-5167, USA
| | - C D Keith
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - D Keller
- University of Virginia, Charlottesville, Virginia 22901, USA
| | | | - M Khachatryan
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - A Khanal
- Florida International University, Miami, Florida 33199, USA
| | - M Khandaker
- Norfolk State University, Norfolk, Virginia 23504, USA
| | - A Kim
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - W Kim
- Kyungpook National University, Daegu 41566, Republic of Korea
| | - F J Klein
- Catholic University of America, Washington, D.C. 20064, USA
| | - V Kubarovsky
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S V Kuleshov
- Institute of Theoretical and Experimental Physics, Moscow, 117259, Russia
- Universidad Técnica Federico Santa María, Casilla 110-V Valparaíso, Chile
| | - M C Kunkel
- Institut für Kernphysik, 52425 Jülich, Germany
| | - L Lanza
- INFN, Sezione di Roma Tor Vergata, 00133 Rome, Italy
| | - P Lenisa
- INFN, Sezione di Ferrara, 44100 Ferrara, Italy
| | - K Livingston
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | | | - D Marchand
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - B McKinnon
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - D G Meekins
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - C A Meyer
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - T Mineeva
- Universidad Técnica Federico Santa María, Casilla 110-V Valparaíso, Chile
| | - V Mokeev
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, 119234 Moscow, Russia
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | | | - A Movsisyan
- INFN, Sezione di Ferrara, 44100 Ferrara, Italy
| | - C Munoz Camacho
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - P Nadel-Turonski
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S Niccolai
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - G Niculescu
- James Madison University, Harrisonburg, Virginia 22807, USA
| | - M Osipenko
- INFN, Sezione di Genova, 16146 Genova, Italy
| | - A I Ostrovidov
- Florida State University, Tallahassee, Florida 32306, USA
| | - M Paolone
- University of South Carolina, Columbia, South Carolina 29208, USA
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | | | - R Paremuzyan
- University of New Hampshire, Durham, New Hampshire 03824-3568, USA
- Yerevan Physics Institute, 375036 Yerevan, Armenia
| | - E Pasyuk
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - D Payette
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - W Phelps
- The George Washington University, Washington, DC 20052, USA
| | - J Pierce
- University of Virginia, Charlottesville, Virginia 22901, USA
| | - O Pogorelko
- Institute of Theoretical and Experimental Physics, Moscow, 117259, Russia
| | - Y Prok
- Christopher Newport University, Newport News, Virginia 23606, USA
- Old Dominion University, Norfolk, Virginia 23529, USA
- University of Virginia, Charlottesville, Virginia 22901, USA
| | | | - B A Raue
- Florida International University, Miami, Florida 33199, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M Ripani
- INFN, Sezione di Genova, 16146 Genova, Italy
| | - D Riser
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - B G Ritchie
- Arizona State University, Tempe, Arizona 85287-1504, USA
| | - A Rizzo
- INFN, Sezione di Roma Tor Vergata, 00133 Rome, Italy
- Università di Roma Tor Vergata, 00133 Rome, Italy
| | - G Rosner
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - F Sabatié
- IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - C Salgado
- Norfolk State University, Norfolk, Virginia 23504, USA
| | - R A Schumacher
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - M L Seely
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - Y G Sharabian
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - U Shrestha
- Ohio University, Athens, Ohio 45701, USA
| | - Iu Skorodumina
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, 119234 Moscow, Russia
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - D Sokhan
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - O Soto
- Universidad Técnica Federico Santa María, Casilla 110-V Valparaíso, Chile
| | - N Sparveris
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - I I Strakovsky
- The George Washington University, Washington, DC 20052, USA
| | - S Strauch
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - M Taiuti
- Università di Genova, 16146 Genova, Italy
| | - J A Tan
- Kyungpook National University, Daegu 41566, Republic of Korea
| | - B Torayev
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - N Tyler
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - M Ungaro
- University of Connecticut, Storrs, Connecticut 06269, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - H Voskanyan
- Yerevan Physics Institute, 375036 Yerevan, Armenia
| | - E Voutier
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - N K Walford
- Catholic University of America, Washington, D.C. 20064, USA
| | - R Wang
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - D P Watts
- University of York, York YO10, United Kingdom
| | - X Wei
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M H Wood
- Canisius College, Buffalo, New York 14208, USA
| | - N Zachariou
- The George Washington University, Washington, DC 20052, USA
- University of York, York YO10, United Kingdom
| | - J Zhang
- Old Dominion University, Norfolk, Virginia 23529, USA
- University of Virginia, Charlottesville, Virginia 22901, USA
| | - Z W Zhao
- Duke University, Durham, North Carolina 27708-0305, USA
- University of South Carolina, Columbia, South Carolina 29208, USA
- University of Virginia, Charlottesville, Virginia 22901, USA
| |
Collapse
|
47
|
Polley MYC, Dickler MN, Johnston S, Goetz MP, de la Haba J, Loibl S, Mehta RS, Bergh J, Roberston J, Barlow W, Liu H, Tenner K, Martin M. Abstract P2-07-05: A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced stage breast cancer treated with first-line endocrine therapy. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p2-07-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: Endocrine based therapy is an effective strategy to manage hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC). However, nearly all patients exhibit/develop either de novo or acquired resistance. While prognostic biomarkers of endocrine responsiveness are well established for the adjuvant treatment in ER+ breast cancer, less is known regarding prognostic and predictive biomarkers of response in the first line ABC setting. We sought to develop a clinical calculator based on clinical criteria for predicting progression-free survival (PFS) and overall survival (OS) of women with HR+/HER2- ABC who will be receiving endocrine monotherapy as first-line treatment for ABC.
Methods: The development of the clinical calculator will be based on data from modern clinical trials in women with HR+/HER2- ABC. The studies to be included in the final analyses are given in Table 1. The control arm data from trials1-6 will form the training dataset (N = 1,223) and be used to construct the clinical prediction models. Variables considered include age, race, ECOG status, disease measurability, body mass index, disease-free interval, number of metastatic sites, locations of metastatic sites, prior endocrine therapy, and prior chemotherapy. Missing values will be imputed using single imputation with all variables included in the imputation model. For continuous variables, restricted cubic splines will be used to determine if non-linear effects may be more appropriate. The Lasso regression will be used as a variable selection technique to reduce the dimensionality of covariates; initially all pairwise interactions will be included in the model. Following Lasso regression, the multivariable Cox proportional hazards models will be constructed for PFS and OS including only variables retained in Lasso. The final model will be internally validated for discrimination and calibration using 10-fold cross-validation. External validation will be performed using control arm data from EGF 30008 (N = 536).
Results: To date, control arm data from four trials (trials 1-4) have been received. The preliminary results presented here are based on pooled data from C40503 and LEA, for which data elements have been harmonized. Models for predicting PFS and OS have good calibration and are associated with bias-corrected C-indices of 0.61 and 0.65, respectively. These models will be updated using pooled data from trials 1-6.
Conclusions: Our preliminary data demonstrate that clinical calculators based on baseline clinical factors can provide accurate prediction of PFS and OS in patients with HR+/HER2- ABC treated with first-line ET. If validated, these tools may be used for risk stratification in future clinical trials and to identify patients who may require more or less aggressive therapy.
Table 1:Studies to be includedTrial NumberTrial NameTrial PISample Size in Control Arm1C40503Maura Dickler152 (letrozole)2LEAMiguel Martin179 (letrozole)3FACTJonas Bergh188 (anastrozole)4FALCONJohn Robertson194 (anastrozole)5S0226Rita Mehta345 (anastrozole)6MONARCH 3Matthew Goetz165 (nonsteroidal AI)7EGF 30008Stephen Johnston536 (letrozole)
Citation Format: Polley M-YC, Dickler MN, Johnston S, Goetz MP, de la Haba J, Loibl S, Mehta RS, Bergh J, Roberston J, Barlow W, Liu H, Tenner K, Martin M. A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced stage breast cancer treated with first-line endocrine therapy [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-07-05.
Collapse
Affiliation(s)
- M-YC Polley
- Mayo Clinic, Rochester, MN; Eli Lilly, Indianapolis, IN; The Royal Marsden NHS Foundation Trust, London, United Kingdom; GEICAM, Madrid, Spain; German Breast Group (GBG), Neu-Isenburg, Germany; University of California, Irvine, Orange, CA; Karolinska Institute, Stockholm, Sweden; University of Nottingham, Nottingham, United Kingdom; Southwest Oncology Group (SWOG), Seattle, WA; Gregorio Marañón University Hospital, Madrid, Spain
| | - MN Dickler
- Mayo Clinic, Rochester, MN; Eli Lilly, Indianapolis, IN; The Royal Marsden NHS Foundation Trust, London, United Kingdom; GEICAM, Madrid, Spain; German Breast Group (GBG), Neu-Isenburg, Germany; University of California, Irvine, Orange, CA; Karolinska Institute, Stockholm, Sweden; University of Nottingham, Nottingham, United Kingdom; Southwest Oncology Group (SWOG), Seattle, WA; Gregorio Marañón University Hospital, Madrid, Spain
| | - S Johnston
- Mayo Clinic, Rochester, MN; Eli Lilly, Indianapolis, IN; The Royal Marsden NHS Foundation Trust, London, United Kingdom; GEICAM, Madrid, Spain; German Breast Group (GBG), Neu-Isenburg, Germany; University of California, Irvine, Orange, CA; Karolinska Institute, Stockholm, Sweden; University of Nottingham, Nottingham, United Kingdom; Southwest Oncology Group (SWOG), Seattle, WA; Gregorio Marañón University Hospital, Madrid, Spain
| | - MP Goetz
- Mayo Clinic, Rochester, MN; Eli Lilly, Indianapolis, IN; The Royal Marsden NHS Foundation Trust, London, United Kingdom; GEICAM, Madrid, Spain; German Breast Group (GBG), Neu-Isenburg, Germany; University of California, Irvine, Orange, CA; Karolinska Institute, Stockholm, Sweden; University of Nottingham, Nottingham, United Kingdom; Southwest Oncology Group (SWOG), Seattle, WA; Gregorio Marañón University Hospital, Madrid, Spain
| | - J de la Haba
- Mayo Clinic, Rochester, MN; Eli Lilly, Indianapolis, IN; The Royal Marsden NHS Foundation Trust, London, United Kingdom; GEICAM, Madrid, Spain; German Breast Group (GBG), Neu-Isenburg, Germany; University of California, Irvine, Orange, CA; Karolinska Institute, Stockholm, Sweden; University of Nottingham, Nottingham, United Kingdom; Southwest Oncology Group (SWOG), Seattle, WA; Gregorio Marañón University Hospital, Madrid, Spain
| | - S Loibl
- Mayo Clinic, Rochester, MN; Eli Lilly, Indianapolis, IN; The Royal Marsden NHS Foundation Trust, London, United Kingdom; GEICAM, Madrid, Spain; German Breast Group (GBG), Neu-Isenburg, Germany; University of California, Irvine, Orange, CA; Karolinska Institute, Stockholm, Sweden; University of Nottingham, Nottingham, United Kingdom; Southwest Oncology Group (SWOG), Seattle, WA; Gregorio Marañón University Hospital, Madrid, Spain
| | - RS Mehta
- Mayo Clinic, Rochester, MN; Eli Lilly, Indianapolis, IN; The Royal Marsden NHS Foundation Trust, London, United Kingdom; GEICAM, Madrid, Spain; German Breast Group (GBG), Neu-Isenburg, Germany; University of California, Irvine, Orange, CA; Karolinska Institute, Stockholm, Sweden; University of Nottingham, Nottingham, United Kingdom; Southwest Oncology Group (SWOG), Seattle, WA; Gregorio Marañón University Hospital, Madrid, Spain
| | - J Bergh
- Mayo Clinic, Rochester, MN; Eli Lilly, Indianapolis, IN; The Royal Marsden NHS Foundation Trust, London, United Kingdom; GEICAM, Madrid, Spain; German Breast Group (GBG), Neu-Isenburg, Germany; University of California, Irvine, Orange, CA; Karolinska Institute, Stockholm, Sweden; University of Nottingham, Nottingham, United Kingdom; Southwest Oncology Group (SWOG), Seattle, WA; Gregorio Marañón University Hospital, Madrid, Spain
| | - J Roberston
- Mayo Clinic, Rochester, MN; Eli Lilly, Indianapolis, IN; The Royal Marsden NHS Foundation Trust, London, United Kingdom; GEICAM, Madrid, Spain; German Breast Group (GBG), Neu-Isenburg, Germany; University of California, Irvine, Orange, CA; Karolinska Institute, Stockholm, Sweden; University of Nottingham, Nottingham, United Kingdom; Southwest Oncology Group (SWOG), Seattle, WA; Gregorio Marañón University Hospital, Madrid, Spain
| | - W Barlow
- Mayo Clinic, Rochester, MN; Eli Lilly, Indianapolis, IN; The Royal Marsden NHS Foundation Trust, London, United Kingdom; GEICAM, Madrid, Spain; German Breast Group (GBG), Neu-Isenburg, Germany; University of California, Irvine, Orange, CA; Karolinska Institute, Stockholm, Sweden; University of Nottingham, Nottingham, United Kingdom; Southwest Oncology Group (SWOG), Seattle, WA; Gregorio Marañón University Hospital, Madrid, Spain
| | - H Liu
- Mayo Clinic, Rochester, MN; Eli Lilly, Indianapolis, IN; The Royal Marsden NHS Foundation Trust, London, United Kingdom; GEICAM, Madrid, Spain; German Breast Group (GBG), Neu-Isenburg, Germany; University of California, Irvine, Orange, CA; Karolinska Institute, Stockholm, Sweden; University of Nottingham, Nottingham, United Kingdom; Southwest Oncology Group (SWOG), Seattle, WA; Gregorio Marañón University Hospital, Madrid, Spain
| | - K Tenner
- Mayo Clinic, Rochester, MN; Eli Lilly, Indianapolis, IN; The Royal Marsden NHS Foundation Trust, London, United Kingdom; GEICAM, Madrid, Spain; German Breast Group (GBG), Neu-Isenburg, Germany; University of California, Irvine, Orange, CA; Karolinska Institute, Stockholm, Sweden; University of Nottingham, Nottingham, United Kingdom; Southwest Oncology Group (SWOG), Seattle, WA; Gregorio Marañón University Hospital, Madrid, Spain
| | - M Martin
- Mayo Clinic, Rochester, MN; Eli Lilly, Indianapolis, IN; The Royal Marsden NHS Foundation Trust, London, United Kingdom; GEICAM, Madrid, Spain; German Breast Group (GBG), Neu-Isenburg, Germany; University of California, Irvine, Orange, CA; Karolinska Institute, Stockholm, Sweden; University of Nottingham, Nottingham, United Kingdom; Southwest Oncology Group (SWOG), Seattle, WA; Gregorio Marañón University Hospital, Madrid, Spain
| |
Collapse
|
48
|
Robertson JFR, Di Leo A, Johnston S, Chia S, Bliss J, Bradbury I, Campbell C. Abstract P4-13-13: Meta-analyses of visceral versus non-visceral metastases treated by AI & SERD agents as 2nd line endocrine therapy (ET) for HR+ breast cancer (BC). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-13-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
There is a prevailing belief that ET for HR+ advanced BC is not as effective in patients with visceral metastases (VM) compared to non-visceral metastases (nVM), particularly with later lines of ET. Recently fulvestrant 500mg (Ful 500), has been reported to have greater efficacy in nVM compared to i) VM treated by Ful 500 but also compared to ii) nVM treated by Ful 250 (2nd line) and iii) nVM treated by aromatase inhibitor (AI), anastrozole (1st Line) – implying both site and agent related efficacy. Absence of significant overall survival (OS) difference in PALOMA 3 (2nd line) has increased the debate regarding when to add CDK 4/6is to ET, especially given the OS advantage for Ful 500 monotherapy in the 1st & 2nd line settings.
Patients & Methods: Anonymised, individual patient level data was obtained from randomised controlled trials (RCTs) involving AI & SERD used as mono-theraphy in 2nd or 3rd Line setting in known HR+ BC. All the trials were Phase 3 double-blind, placebo RCTs. All were rigorously assessed for clinical benefit (CB), progression free survival (PFS), duration of CB (DoCB) and OS. Details of the studies, types of ET and patient numbers are shown in the Table.
Results: Outcome data is presented for each study and then summarised under AI, SERD (Ful 250 or 500) and 'all Ets combined'. Odds ratios (Ors) & hazard ratios (HRs) for VM versus nVM by endocrine agents are shown in the Table.
AgentStudyTotal Pats.HR+ Pats.CBRPFSOSDoCBAI(n)(n)OR (95%Cis)HR (95%Cis)HR (95%Cis)HR (95%Cis)Exe00202301831.181.441.271.50Exe00211931681.151.951.832.12AnaEFECT3403360.941.521.201.10AnaSOFEA2492491.291.181.051.41subtotal7636871.11 (0.84-1.48)1.47*** (1.22-1.79)1.21* (1.01-1.45)1.43** (1.10-1.86)SERDFul 25000202191601.791.701.401.23Ful 25000212041771.281.811.322.06Ful 250EFECT3513450.791.401.311.03Ful 250SOFEA2312310.701.171.242.22Ful 250CONFIRM1521521.131.071.510.84Subtotal9268341.05 (0.75-1.45)1.39*** (1.16-1.67)1.34*** (1.14-1.57)1.36 (0.93-1.98)SERDFul 500CONFIRM1441442.24 (1.12-4.48)1.30 (0.90-1.87)1.33 (1.14-1.57)0.97 (0.55-1.66)All ETsTotal183316651.13 (0.92-1.39)1.42*** (1.26-1.59)1.28*** (1.14-1.44)1.35** (1.09-1.66)
[Pats=Patients; (n)=number; CBR-Clinical Benefit Rate; p-values p<0.05*, p<0.01**, p<0.001***]
Median PFS (months) for nVM for AI, SERD250, SERD500 & ‘all Ets combined’ were 5.4, 5.5, 11.0 & 5.5 respectively: for VM they were 2.9, 3.5, 5.5 & 3.2 respectively.
Median OS (months) for nVM for AI, SERD250, SERD500 & ‘all Ets combined’ was 24.2, 26.0, 35.4 & 25.4 respectively: for VM the figures were 22.8, 20.8, 26.4 & 22.0 respectively.Conclusions:1) In the 2nd line HR+ setting AI & Ful 250 both significantly increased PFS & OS in nVM versus VM. Longer PFS appears due to longer duration of control (DoCB) than increasing the number of patients responding (CBR).
2) Median OS for nVM ranged from 24 – 35 months versus 20.8-26.4 months for VM: for the majority of patients the 2nd line ET setting is not ‘immediately life threating’ and ET is therefore an option to consider.
3) These data on site of disease (nVM vs VM) contribute to the selection of which patients should receive endocrine mono- and which endocrine combination therapy (ie plus mTORi or CDK4/6i) in the second line setting.
Citation Format: Robertson JFR, Di Leo A, Johnston S, Chia S, Bliss J, Bradbury I, Campbell C. Meta-analyses of visceral versus non-visceral metastases treated by AI & SERD agents as 2nd line endocrine therapy (ET) for HR+ breast cancer (BC) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-13-13.
Collapse
Affiliation(s)
- JFR Robertson
- University of Nottingham, Nottingham, Nottinghamshire, United Kingdom; Sandra Pitigliani Medical Oncology Unit, Hospital of Prato, Prato, Italy; Royal Marsden NHS Foundation Trust, London, United Kingdom; British Columbia Cancer Agency, Vancouver, Canada; The Institute of Cancer Research, London, United Kingdom; Frontier Science, Kincraig, Inverness-shire, United Kingdom
| | - A Di Leo
- University of Nottingham, Nottingham, Nottinghamshire, United Kingdom; Sandra Pitigliani Medical Oncology Unit, Hospital of Prato, Prato, Italy; Royal Marsden NHS Foundation Trust, London, United Kingdom; British Columbia Cancer Agency, Vancouver, Canada; The Institute of Cancer Research, London, United Kingdom; Frontier Science, Kincraig, Inverness-shire, United Kingdom
| | - S Johnston
- University of Nottingham, Nottingham, Nottinghamshire, United Kingdom; Sandra Pitigliani Medical Oncology Unit, Hospital of Prato, Prato, Italy; Royal Marsden NHS Foundation Trust, London, United Kingdom; British Columbia Cancer Agency, Vancouver, Canada; The Institute of Cancer Research, London, United Kingdom; Frontier Science, Kincraig, Inverness-shire, United Kingdom
| | - S Chia
- University of Nottingham, Nottingham, Nottinghamshire, United Kingdom; Sandra Pitigliani Medical Oncology Unit, Hospital of Prato, Prato, Italy; Royal Marsden NHS Foundation Trust, London, United Kingdom; British Columbia Cancer Agency, Vancouver, Canada; The Institute of Cancer Research, London, United Kingdom; Frontier Science, Kincraig, Inverness-shire, United Kingdom
| | - J Bliss
- University of Nottingham, Nottingham, Nottinghamshire, United Kingdom; Sandra Pitigliani Medical Oncology Unit, Hospital of Prato, Prato, Italy; Royal Marsden NHS Foundation Trust, London, United Kingdom; British Columbia Cancer Agency, Vancouver, Canada; The Institute of Cancer Research, London, United Kingdom; Frontier Science, Kincraig, Inverness-shire, United Kingdom
| | - I Bradbury
- University of Nottingham, Nottingham, Nottinghamshire, United Kingdom; Sandra Pitigliani Medical Oncology Unit, Hospital of Prato, Prato, Italy; Royal Marsden NHS Foundation Trust, London, United Kingdom; British Columbia Cancer Agency, Vancouver, Canada; The Institute of Cancer Research, London, United Kingdom; Frontier Science, Kincraig, Inverness-shire, United Kingdom
| | - C Campbell
- University of Nottingham, Nottingham, Nottinghamshire, United Kingdom; Sandra Pitigliani Medical Oncology Unit, Hospital of Prato, Prato, Italy; Royal Marsden NHS Foundation Trust, London, United Kingdom; British Columbia Cancer Agency, Vancouver, Canada; The Institute of Cancer Research, London, United Kingdom; Frontier Science, Kincraig, Inverness-shire, United Kingdom
| |
Collapse
|
49
|
Goetz MP, Johnston S, Martin M, Tokunaga E, Park IH, Huober J, Toi M, Price GL, Boye M, Li L, Forrester T, Gainford C, Gable J, Carter GC, Sood A, DiLeo A. Abstract P6-16-01: Health-related quality of life in MONARCH 3: Abemaciclib plus an aromatase inhibitor as initial therapy in women with HR+, HER2- advanced breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-16-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: In the MONARCH 3 trial, abemaciclib plus an aromatase inhibitor (AI) significantly improved progression free survival and overall response rate with a generally tolerable safety profile compared to placebo plus AI. Here we report patient-reported outcomes (PRO) including health-related quality of life (Qol), functioning, and symptoms.
Methods: MONARCH 3 was a double-blind, randomized phase III study of abemaciclib or placebo plus an AI in 493 post-menopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer with no prior systemic therapy in the advanced setting. Two European Organization for Research and Treatment of Cancer (EORTC) questionnaires were included: Quality of Life Questionnaire (QLQ)-Core 30 (C30) and the EORTC QLQ-Breast 23 (BR23) that were assessed at baseline, every 2 cycles through cycle 19, then every 3 cycles until treatment discontinuation, and at short-term follow up. Higher scores on functional and health status/QoL outcomes indicate higher/better levels of functioning or health; conversely higher scores on symptom outcomes indicate higher/worse levels of symptom burden. Between-arm comparisons of change from baseline were conducted using mixed model methods. Statistical significance was set at 0.05 and clinical meaningfulness was set at ≥10 points on a 0-100 scale1.
Results: PRO completion rates were >91% through cycle 19; duration of treatment was longer for abemaciclib plus AI patients (median number of cycles 19 vs.15). Compared to the placebo arm, diarrhea PRO scores in the abemaciclib arm showed a clinically (18.68 points) and statistically significant (p<0.001) increase/worsening. By-cycle analysis showed group mean diarrhea scores returned to near-baseline levels post-therapy. Other symptom PROs showed statistically significant (<0.05) but not clinically meaningful differences; fatigue (4.96; p=0.004), systemic therapy side effects (4.48, p<0.001), appetite loss (4.03; p=0.034), and nausea/vomiting (2.77; p=0.013). These results were consistent with the investigator-reported treatment emergent adverse events (TEAEs). Several non-symptom results were also statistically significant but not clinically meaningful including global health/health status (-4.36; p=0.003), role function (-4.25; p=0.025), social function (-3.41, p=0.047), and body image (-5.11, p=0.009). No statistically significant between-treatment differences were observed for physical, emotional, and cognitive functioning or for symptoms of pain, dyspnea, insomnia, constipation, or financial difficulties.
Conclusions: The addition of abemaciclib to an AI resulted in clinically and statistically significant changes in diarrhea without clinically meaningful differences in other symptom scores. Increased GI-related symptoms were consistent with the manageable, reversible AE profile; the highest symptom burden was reported during early visits. No clinically meaningful differences in global health status or functional scores were observed.
ClinicalTrials.gov: NCT02246621
Reference:
1. Osoba D et al. J Clin Oncol 2002;20(14):3106-13.
Citation Format: Goetz MP, Johnston S, Martin M, Tokunaga E, Park IH, Huober J, Toi M, Price GL, Boye M, Li L, Forrester T, Gainford C, Gable J, Carter GC, Sood A, DiLeo A. Health-related quality of life in MONARCH 3: Abemaciclib plus an aromatase inhibitor as initial therapy in women with HR+, HER2- advanced breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-16-01.
Collapse
Affiliation(s)
- MP Goetz
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - S Johnston
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - M Martin
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - E Tokunaga
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - IH Park
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - J Huober
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - M Toi
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - GL Price
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - M Boye
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - L Li
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - T Forrester
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - C Gainford
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - J Gable
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - GC Carter
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - A Sood
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - A DiLeo
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| |
Collapse
|
50
|
Turner N, Garcia-Murillas I, Chopra N, Comino-Mendez I, Beaney M, Tovey H, Cutts R, Swift C, Kriplani D, Afentakis M, Hrebien S, Walsh G, Johnston S, Ring A, Russell S, Evans A, Skene A, Wheatley D, Dowsett M, Smith I. Abstract P4-01-01: Molecular residual disease detection with circulating tumor DNA analysis predicts relapse in patients with early stage breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-01-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background. Detection of circulating tumor DNA (ctDNA) after treatment of early stage breast cancer may identify molecular residual disease. In a prior proof-of-principle study we demonstrated that detection of ctDNA predicted relapse with high accuracy (Garcia-Murillas et al Science Trans Med 2015). We conducted an independent, prospective, multi-centre validation study.
Methods. In this validation study, a cohort of 170 early stage breast cancer patients were recruited from five hospitals into two prospective sample collection studies. Patients were scheduled to receive standard chemotherapy, surgery +/- radiotherapy, adjuvant endocrine therapy and HER2 antibodies as appropriate. Plasma samples were collected for ctDNA analysis at baseline, post-surgery, three monthly for the first year of follow-up, and six monthly thereafter and shipped to a central lab for processing. Using previously established criteria, tumor was sequenced to identify somatic mutations that were tracked by digital PCR in DNA extracted from 4mls of plasma at all available time points. Buffy coat DNA was analysed at all time-points to control for clonal haematopoesis of indeterminate potential (CHIP) detection. The primary endpoint was to compare invasive disease free survival between patients with and without detection of ctDNA after treatment. A combined analysis of this validation study, and the prior proof-of-principle study, was also conducted to analyse secondary endpoints.
Results. After tumor sequencing, 101 patients from the validation study had at least one mutation to track. At median 35.5 months follow-up, ctDNA was detected in plasma of 15.8% (16/101) patients. Detection of ctDNA strongly predicted relapse, hazard ratio 24.5 (95% CI 6.5 to 93.2, P<0.001 time-dependent Cox model), and was predictive of relapse in all tumor subtypes.
In the combined analysis (N=144), lead-time between ctDNA detection and relapse was 10.7 months (95% CI 7.7-17.0). Six patients had a clinical relapse that was not detected by ctDNA prior to relapse. These patients had a distinct pattern of oligo-metastatic relapse, 3 patients with brain-only metastases (P=0.0068), 1 ovarian oligo-metastasis and 2 local disease recurrence. The level of ctDNA in baseline plasma, prior to treatment, was associated with tumor subtype, highest in triple negative breast cancer (P=0.0036).
Conclusion. Detection of ctDNA after treatment is associated with a high risk of future relapse in early-stage breast cancer. Prospective studies are required to assess the potential of molecular residual disease detection to guide adjuvant therapy.
Citation Format: Turner N, Garcia-Murillas I, Chopra N, Comino-Mendez I, Beaney M, Tovey H, Cutts R, Swift C, Kriplani D, Afentakis M, Hrebien S, Walsh G, Johnston S, Ring A, Russell S, Evans A, Skene A, Wheatley D, Dowsett M, Smith I. Molecular residual disease detection with circulating tumor DNA analysis predicts relapse in patients with early stage breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-01-01.
Collapse
Affiliation(s)
- N Turner
- The Institute of Cancer Research, Lomdon, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Hinchingbrooke Hospital, Hungtindon, United Kingdom; Poole General Hospital, Poole, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
| | - I Garcia-Murillas
- The Institute of Cancer Research, Lomdon, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Hinchingbrooke Hospital, Hungtindon, United Kingdom; Poole General Hospital, Poole, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
| | - N Chopra
- The Institute of Cancer Research, Lomdon, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Hinchingbrooke Hospital, Hungtindon, United Kingdom; Poole General Hospital, Poole, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
| | - I Comino-Mendez
- The Institute of Cancer Research, Lomdon, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Hinchingbrooke Hospital, Hungtindon, United Kingdom; Poole General Hospital, Poole, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
| | - M Beaney
- The Institute of Cancer Research, Lomdon, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Hinchingbrooke Hospital, Hungtindon, United Kingdom; Poole General Hospital, Poole, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
| | - H Tovey
- The Institute of Cancer Research, Lomdon, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Hinchingbrooke Hospital, Hungtindon, United Kingdom; Poole General Hospital, Poole, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
| | - R Cutts
- The Institute of Cancer Research, Lomdon, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Hinchingbrooke Hospital, Hungtindon, United Kingdom; Poole General Hospital, Poole, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
| | - C Swift
- The Institute of Cancer Research, Lomdon, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Hinchingbrooke Hospital, Hungtindon, United Kingdom; Poole General Hospital, Poole, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
| | - D Kriplani
- The Institute of Cancer Research, Lomdon, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Hinchingbrooke Hospital, Hungtindon, United Kingdom; Poole General Hospital, Poole, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
| | - M Afentakis
- The Institute of Cancer Research, Lomdon, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Hinchingbrooke Hospital, Hungtindon, United Kingdom; Poole General Hospital, Poole, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
| | - S Hrebien
- The Institute of Cancer Research, Lomdon, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Hinchingbrooke Hospital, Hungtindon, United Kingdom; Poole General Hospital, Poole, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
| | - G Walsh
- The Institute of Cancer Research, Lomdon, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Hinchingbrooke Hospital, Hungtindon, United Kingdom; Poole General Hospital, Poole, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
| | - S Johnston
- The Institute of Cancer Research, Lomdon, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Hinchingbrooke Hospital, Hungtindon, United Kingdom; Poole General Hospital, Poole, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
| | - A Ring
- The Institute of Cancer Research, Lomdon, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Hinchingbrooke Hospital, Hungtindon, United Kingdom; Poole General Hospital, Poole, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
| | - S Russell
- The Institute of Cancer Research, Lomdon, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Hinchingbrooke Hospital, Hungtindon, United Kingdom; Poole General Hospital, Poole, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
| | - A Evans
- The Institute of Cancer Research, Lomdon, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Hinchingbrooke Hospital, Hungtindon, United Kingdom; Poole General Hospital, Poole, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
| | - A Skene
- The Institute of Cancer Research, Lomdon, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Hinchingbrooke Hospital, Hungtindon, United Kingdom; Poole General Hospital, Poole, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
| | - D Wheatley
- The Institute of Cancer Research, Lomdon, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Hinchingbrooke Hospital, Hungtindon, United Kingdom; Poole General Hospital, Poole, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
| | - M Dowsett
- The Institute of Cancer Research, Lomdon, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Hinchingbrooke Hospital, Hungtindon, United Kingdom; Poole General Hospital, Poole, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
| | - I Smith
- The Institute of Cancer Research, Lomdon, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Hinchingbrooke Hospital, Hungtindon, United Kingdom; Poole General Hospital, Poole, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
| |
Collapse
|